The	O
impact	O
of	O
pediatric	O
chronic	O
kidney	O
disease	O
-LRB-CKD-RRB-	O
on	O
acquisition	O
of	O
volumetric	O
bone	O
mineral	O
density	O
-LRB-BMD-RRB-	O
and	O
cortical	O
dimensions	O
is	O
lacking	O
.	O
To	O
address	O
this	O
issue	O
we	O
obtained	B-tomography
tibia	I-tomography
quantitative	I-tomography
computed	I-tomography
tomography	I-tomography
scans	I-tomography
from	I-tomography
103	O
patients	O
age	O
5-21	O
years	O
with	O
CKD	O
-LRB-26	O
on	O
dialysis-RRB-	O
at	O
baseline	O
and	O
12	O
months	O
later	O
.	O
Gender,	O
ethnicity,	O
tibia	O
length	O
and/or	O
age-specific	O
Z-scores	O
were	O
generated	O
for	O
trabecular	O
and	O
cortical	O
BMD,	O
cortical	O
area,	O
periosteal	O
and	O
endosteal	O
circumference,	O
and	O
muscle	O
area	O
based	O
on	O
over	O
700	O
reference	O
subjects	O
.	O
Muscle	O
area,	O
cortical	O
area,	O
and	O
periosteal	O
and	O
endosteal	O
Z-scores	O
were	O
significantly	O
lower	O
at	O
baseline	O
compared	O
to	O
the	O
reference	O
cohort	O
.	O
Cortical	O
BMD,	O
cortical	O
area	O
and	O
periosteal	O
Z-scores	O
all	O
exhibited	O
a	O
significant	O
further	O
decrease	O
over	O
12	O
months	O
.	O
Higher	O
parathyroid	O
hormone	O
levels	O
were	O
associated	O
with	O
significantly	O
greater	O
increases	O
in	O
trabecular	O
BMD	O
and	O
decreases	O
in	O
cortical	O
BMD	O
in	O
younger	O
patients	O
-LRB-significant	O
interaction	O
terms	O
for	O
trabecular	O
BMD	O
and	O
cortical	O
BMD-RRB-	O
.	O
The	O
estimated	O
GFR	O
was	O
not	O
associated	O
with	O
changes	O
in	O
BMD	O
Z-scores	O
independent	O
of	O
parathyroid	O
hormone	O
.	O
Changes	O
in	O
muscle	O
and	O
cortical	O
area	O
were	O
significantly	O
and	O
positively	O
associated	O
in	O
control	O
subjects	O
but	O
not	O
in	O
CKD	O
patients	O
.	O
Thus,	O
children	O
and	O
adolescents	O
with	O
CKD	O
have	O
progressive	O
cortical	O
bone	O
deficits	O
related	O
to	O
secondary	O
hyperparathyroidism	O
and	O
potential	O
impairment	O
of	O
the	O
functional	O
muscle-bone	O
unit	O
.	O
Interventions	O
are	O
needed	O
to	O
enhance	O
bone	O
accrual	O
in	O
childhood-onset	O
CKD	O
.	O
Introduction	O
Children	O
with	O
chronic	O
kidney	O
disease	O
-LRB-CKD-RRB-	O
have	O
multiple	O
risk	O
factors	O
for	O
impaired	O
bone	O
accrual,	O
including	O
poor	O
growth,	O
delayed	O
maturation,	O
muscle	O
deficits,	O
decreased	O
physical	O
activity,	O
abnormal	O
mineral	O
metabolism	O
and	O
secondary	O
hyperparathyroidism	O
.	O
We	O
recently	O
reported	O
that	O
childhood-onset	O
CKD	O
was	O
associated	O
with	O
significant	O
deficits	O
in	O
cortical	O
volumetric	O
bone	O
mineral	O
density	O
-LRB-BMD-RRB-,	O
cortical	O
dimensions	O
and	O
muscle	O
area,	O
as	O
measured	O
by	B-tomography
peripheral	I-tomography
quantitative	I-tomography
computed	I-tomography
tomography	I-tomography
-LRB-pQCT-RRB-.1,	I-tomography
2	I-tomography
CKD	O
was	O
also	O
associated	O
with	O
elevated	O
trabecular	O
BMD	O
in	O
younger	O
participants	O
only	O
.	O
The	O
cross-sectional	O
design	O
limited	O
the	O
assessment	O
of	O
determinants	O
of	O
bone	O
abnormalities	O
and	O
associations	O
between	O
bone	O
and	O
muscle	O
outcomes	O
.	O
To	O
our	O
knowledge,	O
longitudinal	O
studies	O
of	O
bone	O
accrual	O
in	O
childhood	O
CKD,	O
in	O
the	O
absence	O
of	O
intervening	O
renal	O
transplantation,	O
are	O
limited	O
to	O
series	O
of	O
7-18	O
participants.3-6	O
These	O
studies	O
were	O
further	O
limited	O
by	O
the	O
use	O
of	O
dual	O
energy	O
x-ray	O
absorptiometry	O
-LRB-DXA-RRB-	O
measures	O
of	O
areal	O
BMD	O
.	O
DXA	O
is	O
a	O
two-dimensional	O
projection	O
technique	O
that	O
obscures	O
distinct	O
CKD	O
effects	O
on	O
trabecular	O
and	O
cortical	O
bone,7	O
and	O
underestimates	O
volumetric	O
BMD	O
in	O
children	O
with	O
growth	O
failure.8	O
The	O
objectives	O
of	O
this	O
prospective	O
cohort	O
study	O
were:	O
1-RRB-	O
to	O
assess	O
changes	O
in	O
trabecular	O
and	O
cortical	O
volumetric	O
BMD	O
and	O
cortical	O
dimensions	O
over	O
a	O
one	O
year	O
interval	O
in	O
children	O
and	O
adolescents	O
with	O
mild	O
to	O
severe	O
CKD,	O
2-RRB-	O
to	O
identify	O
correlates	O
of	O
changes	O
in	O
pQCT	O
parameters	O
including	O
CKD	O
progression,	O
intact	O
parathyroid	O
hormone	O
-LRB-iPTH-RRB-	O
levels,	O
and	O
medications,	O
and	O
3-RRB-	O
to	O
assess	O
the	O
relations	O
between	O
changes	O
in	O
muscle	O
area	O
and	O
bone	O
dimensions	O
-LRB-the	O
functional	O
muscle-bone	O
unit-RRB-	O
compared	O
with	O
longitudinal	O
data	O
in	O
healthy	O
reference	O
participants	O
.	O
Results	O
Participant	O
Characteristics	O
This	O
report	O
describes	O
103	O
CKD	O
participants	O
with	O
two	O
pQCT	O
scans,	O
a	O
median	O
12.5	O
months	O
apart	O
-LSB-interquartile	O
range	O
-LRB-IQR-RRB-	O
12.1,	O
13.2-RSB-,	O
including	O
83	O
from	O
the	O
prior	O
cross-sectional	O
study.2	O
The	O
focus	O
of	O
this	O
study	O
is	O
determinants	O
of	O
changes	O
in	O
bone,	O
therefore,	O
this	O
cohort	O
includes	O
an	O
additional	O
20	O
participants	O
that	O
were	O
ineligible	O
for	O
the	O
prior	O
study	O
due	O
to	O
a	O
history	O
of	O
solid	O
organ	O
transplantation	O
.	O
All	O
prior	O
renal	O
transplant	O
recipients	O
in	O
this	O
study	O
were	O
on	O
dialysis;	O
median	O
interval	O
since	O
transplantation	O
of	O
5.1	O
-LRB-IQR	O
3.9,	O
7.2-RRB-	O
years	O
and	O
a	O
median	O
interval	O
since	O
starting	O
dialysis	O
of	O
11	O
-LRB-IQR	O
2,	O
56-RRB-	O
months	O
.	O
Baseline	O
characteristics	O
are	O
summarized	O
in	O
Table	O
1	O
.	O
The	O
reference	O
participants	O
have	O
been	O
described.2,	O
9,	O
10	O
Compared	O
with	O
the	O
non-dialysis	O
CKD,	O
dialysis	O
participants	O
were	O
significantly	O
older,	O
more	O
likely	O
to	O
be	O
of	O
black	O
race	O
and	O
more	O
likely	O
to	O
have	O
focal	O
segmental	O
glomerulosclerosis	O
-LRB-FSGS-RRB-	O
.	O
Clinical	O
Course	O
Laboratory	O
results,	O
estimated	O
glomerular	O
filtration	O
rate	O
-LRB-eGFR-RRB-	O
and	O
medications	O
are	O
summarized	O
in	O
Table	O
2	O
.	O
There	O
was	O
a	O
significant	O
decline	O
in	O
renal	O
function	O
over	O
the	O
study	O
period	O
in	O
non-dialysis	O
CKD	O
participants	O
with	O
a	O
median	O
decrease	O
of	O
2	O
-LRB-IQR	O
-7	O
to	O
1-RRB-	O
ml/min/1.73m2	O
.	O
Two	O
participants	O
initiated	O
dialysis	O
.	O
Serum	O
iPTH	O
and	O
phosphorus	O
levels	O
increased	O
significantly	O
in	O
the	O
non-dialysis	O
population	O
.	O
The	O
proportion	O
of	O
non-dialysis	O
participants	O
above	O
the	O
normal	O
iPTH	O
range	O
-LRB->65	O
pg/ml-RRB-	O
increased	O
from	O
39	O
to	O
52%	O
over	O
the	O
study	O
.	O
The	O
mean	O
iPTH	O
was	O
above	O
the	O
pediatric	O
Kidney	O
Disease	O
Outcome	O
Quality	O
Initiative	O
-LRB-KDOQI-RRB-	O
CKD	O
stage-specific	O
target	O
range	O
in	O
32	O
-LRB-42%-RRB-	O
and	O
13	O
-LRB-50%-RRB-	O
of	O
non-dialysis	O
and	O
dialysis	O
participants,	O
respectively,	O
and	O
above	O
the	O
lower	O
European	O
target	O
ranges	O
in	O
38	O
-LRB-49%-RRB-	O
and	O
18	O
-LRB-69%-RRB-,	O
respectively.11,	O
12	O
Among	O
the	O
20	O
participants	O
with	O
a	O
history	O
of	O
prior	O
transplantation,	O
7	O
received	O
glucocorticoids	O
and	O
9	O
received	O
calcineurin	O
inhibitors	O
during	O
the	O
study	O
period	O
.	O
The	O
remainder	O
of	O
participants	O
treated	O
with	O
glucocorticoids	O
had	O
a	O
diagnosis	O
of	O
FSGS,	O
systemic	O
inflammatory	O
disease	O
or	O
IgA	O
nephropathy	O
.	O
Six	O
CKD	O
participants	O
sustained	O
a	O
total	O
of	O
7	O
fractures	O
-LRB-1	O
tibia/fibula,	O
1	O
radius/ulna	O
and	O
5	O
foot/toe-RRB-	O
during	O
the	O
study	O
interval	O
-LRB-57/1,000	O
patient-years-RRB-	O
.	O
Peripheral	O
QCT	O
Outcomes	O
Table	O
3	O
summarizes	O
pQCT	O
Z-scores	O
in	O
CKD	O
participants	O
.	O
Trabecular	O
BMD	O
Overall,	O
trabecular	O
BMD	O
Z-scores	O
did	O
not	O
change	O
significantly	O
in	O
all	O
participants	O
combined,	O
or	O
within	O
the	O
non-dialysis	O
and	O
dialysis	O
groups	O
.	O
The	O
multivariate	O
regression	O
model	O
for	O
changes	O
in	O
trabecular	O
BMD	O
Z-score	O
demonstrated	O
that	O
a	O
greater	O
mean	O
iPTH	O
level	O
was	O
associated	O
with	O
a	O
significantly	O
greater	O
change	O
in	O
trabecular	O
BMD	O
Z-score	O
-LRB-p<0.001-RRB-	O
and	O
this	O
effect	O
was	O
limited	O
to	O
the	O
younger	O
participants	O
-LRB-interaction,	O
p=0.001-RRB-,	O
adjusted	O
for	O
baseline	O
trabecular	O
BMD	O
Z-score	O
.	O
These	O
results	O
are	O
illustrated	O
in	O
Figure	O
1,	O
according	O
to	O
age	O
<	O
or	O
the	O
median	O
of	O
14	O
years	O
.	O
Changes	O
in	O
trabecular	O
BMD	O
Z-scores	O
were	O
significantly	O
greater	O
in	O
the	O
11	O
participants	O
that	O
had	O
elevated	O
iPTH	O
levels	O
by	O
European	O
targets	O
only,	O
compared	O
to	O
the	O
47	O
without	O
elevated	O
iPTH	O
by	O
either	O
target	O
-LRB-p=0.04-RRB-	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
the	O
45	O
participants	O
above	O
both	O
targets	O
.	O
Lower	O
baseline	O
eGFR	O
was	O
associated	O
with	O
greater	O
increases	O
in	O
trabecular	O
BMD	O
Z-score	O
-LRB-p<0.03-RRB-	O
and	O
analyses	O
stratified	O
on	O
median	O
age	O
suggested	O
this	O
effect	O
was	O
more	O
pronounced	O
in	O
the	O
younger	O
participants	O
.	O
The	O
association	O
between	O
change	O
in	O
trabecular	O
BMD	O
Z-score	O
and	O
baseline	O
eGFR	O
was	O
eliminated	O
when	O
the	O
models	O
were	O
adjusted	O
for	O
mean	O
iPTH	O
levels	O
.	O
Changes	O
in	O
trabecular	O
BMD-Z	O
scores	O
were	O
not	O
associated	O
with	O
change	O
in	O
eGFR,	O
etiology	O
of	O
CKD,	O
interval	O
since	O
CKD	O
diagnosis,	O
concurrent	O
recombinant	O
growth	O
hormone	O
-LRB-rhGH-RRB-,	O
glucocorticoid,	O
calcitriol	O
or	O
phosphate	O
binder	O
treatment,	O
or	O
physical	O
activity	O
in	O
univariate	O
or	O
multivariate	O
models	O
.	O
Cortical	O
BMD	O
At	O
baseline,	O
cortical	O
BMD	O
Z-scores	O
were	O
not	O
significantly	O
lower	O
in	O
CKD	O
participants	O
vs	O
reference	O
participants	O
overall	O
-LRB-p=0.06-RRB-	O
.	O
Baseline	O
cortical	O
BMD	O
Z-scores	O
were	O
inversely	O
associated	O
with	O
baseline	O
iPTH	O
concentrations	O
in	O
CKD	O
participants	O
-LRB-r=-0.25,	O
p=0.01-RRB-	O
.	O
Cortical	O
BMD	O
Z-scores	O
decreased	O
significantly	O
within	O
all	O
participants	O
combined	O
-LRB-p=0.02-RRB-	O
.	O
In	O
the	O
multivariate	O
regression	O
model	O
of	O
changes	O
in	O
cortical	O
BMD	O
Z-score,	O
higher	O
mean	O
iPTH	O
levels	O
were	O
associated	O
with	O
greater	O
declines	O
in	O
cortical	O
BMD	O
Z-score	O
-LRB-p=0.02-RRB-	O
and	O
this	O
association	O
was	O
marginally	O
greater	O
in	O
the	O
younger	O
participants	O
-LRB-interaction	O
p=0.05-RRB-	O
.	O
Among	O
participants	O
<	O
14	O
years	O
of	O
age,	O
a	O
mean	O
iPTH	O
level	O
greater	O
than	O
the	O
KDOQI	O
target	O
range	O
was	O
associated	O
with	O
a	O
0.29	O
greater	O
decline	O
in	O
cortical	O
BMD	O
Z-score	O
compared	O
with	O
those	O
within	O
or	O
below	O
the	O
target	O
range	O
.	O
Declines	O
in	O
cortical	O
BMD	O
Z-scores	O
were	O
significantly	O
greater	O
in	O
the	O
11	O
participants	O
that	O
had	O
elevated	O
iPTH	O
levels	O
by	O
European	O
targets	O
only,	O
compared	O
to	O
the	O
47	O
without	O
elevated	O
iPTH	O
by	O
either	O
target	O
-LRB-p=0.005-RRB-	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
the	O
45	O
participants	O
above	O
both	O
targets	O
.	O
Changes	O
in	O
cortical	O
BMD	O
Z-scores	O
were	O
not	O
associated	O
with	O
baseline	O
eGFR,	O
change	O
in	O
eGFR,	O
underlying	O
renal	O
disease,	O
interval	O
since	O
CKD	O
diagnosis,	O
medications	O
-LRB-concurrent	O
rhGh,	O
glucocorticoid,	O
calcitriol	O
or	O
phosphate	O
binders-RRB-	O
or	O
physical	O
activity	O
.	O
Cortical	O
Dimensions	O
At	O
baseline,	O
section	O
modulus	O
-LRB-a	O
summary	O
measure	O
of	O
cortical	O
dimensions	O
and	O
strength-RRB-,	O
cortical	O
area,	O
and	O
periosteal	O
and	O
endosteal	O
circumference	O
Z-scores	O
were	O
significantly	O
lower	O
in	O
the	O
CKD	O
participants	O
-LRB-all	O
p<0.01-RRB-,	O
vs	O
reference	O
participants	O
.	O
At	O
baseline,	O
iPTH	O
levels	O
were	O
positively	O
associated	O
with	O
endosteal	O
circumference	O
Z-scores	O
-LRB-r=0.30,	O
p=0.003-RRB-	O
and	O
negatively	O
with	O
cortical	O
area	O
Z-score	O
-LRB-r=-0.25,	O
p=0.01-RRB-	O
but	O
were	O
not	O
associated	O
with	O
periosteal	O
circumference	O
or	O
section	O
modulus	O
Z-scores	O
-LRB-p>0.4-RRB-	O
.	O
Over	O
the	O
follow-up	O
interval,	O
cortical	O
area	O
Z-scores	O
decreased	O
significantly	O
within	O
non-dialysis	O
CKD	O
and	O
dialysis	O
participants	O
.	O
Periosteal	O
circumference	O
Z-scores	O
decreased	O
significantly	O
in	O
all	O
participants	O
combined	O
-LRB-p<0.009-RRB-	O
.	O
In	O
the	O
multivariable	O
model	O
for	O
changes	O
in	O
cortical	O
area	O
Z-score,	O
baseline	O
eGFR,	O
change	O
in	O
eGFR,	O
mean	O
iPTH	O
levels,	O
disease	O
characteristics	O
and	O
medications	O
were	O
not	O
significant	O
.	O
The	O
multivariable	O
models	O
for	O
changes	O
in	O
endosteal	O
and	O
periosteal	O
circumference	O
Z-scores	O
both	O
demonstrated	O
a	O
positive	O
association	O
with	O
higher	O
mean	O
iPTH	O
levels	O
-LRB-p=0.05	O
and	O
p=0.017-RRB-	O
.	O
None	O
of	O
the	O
changes	O
in	O
cortical	O
dimensions	O
was	O
associated	O
with	O
baseline	O
or	O
changes	O
in	O
renal	O
function,	O
diagnostic	O
category,	O
physical	O
activity,	O
or	O
glucocorticoid,	O
calcitriol	O
or	O
phosphate	O
binder	O
therapy	O
.	O
The	O
analyses	O
of	O
rhGH	O
associations	O
with	O
bone	O
outcomes	O
were	O
limited	O
to	O
the	O
58	O
participants	O
<	O
16	O
years	O
of	O
age,	O
including	O
8	O
treated	O
with	O
rhGH	O
for	O
a	O
minimum	O
of	O
6	O
months	O
over	O
the	O
study	O
interval	O
.	O
Concurrent	O
rhGH	O
therapy	O
was	O
associated	O
with	O
greater	O
increases	O
in	O
section	O
modulus	O
-LSB-0.51	O
-LRB-95%	O
C.I	O
0.22,	O
0.79,	O
p=0.001-RRB--RSB-	O
and	O
cortical	O
area	O
Z-scores	O
-LSB-0.27	O
-LRB--0.05,	O
0.60-RRB-,	O
p=0.10-RRB--RSB-;	O
however,	O
the	O
results	O
were	O
significant	O
for	O
section	O
modulus	O
only	O
.	O
Concurrent	O
rhGH	O
was	O
not	O
associated	O
with	O
significant	O
changes	O
in	O
periosteal	O
-LSB-0.10	O
-LRB--0.15,	O
0.35-RRB--RSB-	O
or	O
endosteal	O
-LSB-0.15	O
-LRB--0.10,	O
0.40-RRB--RSB-	O
circumference	O
Z-scores	O
.	O
Muscle	O
and	O
Fat	O
Cross-Sectional	O
Area	O
Z-scores	O
At	O
the	O
baseline	O
visit,	O
mean	O
muscle	O
area	O
Z-scores	O
in	O
CKD	O
participants	O
were	O
lower	O
vs	O
reference	O
participants	O
-LRB-p=0.001-RRB-	O
.	O
Over	O
the	O
follow-up	O
period,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
muscle	O
area	O
Z-scores	O
in	O
non-dialysis	O
CKD	O
participants	O
and	O
a	O
non-significant	O
decrease	O
in	O
dialysis	O
participants	O
.	O
In	O
the	O
multivariable	O
model	O
for	O
changes	O
in	O
muscle	O
area	O
Z-score,	O
none	O
of	O
the	O
participant,	O
disease	O
or	O
treatment	O
characteristics	O
were	O
significant	O
.	O
At	O
the	O
baseline	O
visit,	O
mean	O
fat	O
area	O
Z-scores	O
in	O
CKD	O
participants	O
were	O
not	O
significantly	O
different	O
vs	O
reference	O
participants	O
and	O
the	O
small	O
decline	O
was	O
not	O
significant	O
.	O
In	O
the	O
multivariable	O
regression	O
model	O
for	O
changes,	O
concurrent	O
rhGH	O
therapy	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
fat	O
area	O
Z-scores	O
-LRB-p=0.002-RRB-	O
.	O
Muscle	O
Force	O
and	O
Physical	O
Activity	O
Table	O
3	O
summarizes	O
muscle	O
force	O
Z-scores	O
and	O
physical	O
activity	O
results	O
.	O
At	O
baseline,	O
CKD	O
participants	O
had	O
significantly	O
lower	O
muscle	O
force	O
Z-scores	O
vs	O
reference	O
participants	O
-LRB-p<0.001-RRB-	O
.	O
Muscle	O
force	O
adjusted	O
for	O
muscle	O
CSA	O
was	O
11.9%	O
-LRB-95%	O
CI:	O
4.7,	O
18.5;	O
p=0.002-RRB-	O
lower	O
in	O
non-dialysis	O
CKD	O
participants	O
and	O
16.2%	O
-LRB-5.1,	O
26,	O
p=0.006-RRB-	O
lower	O
in	O
dialysis	O
CKD	O
participants,	O
compared	O
with	O
the	O
reference	O
participants	O
.	O
Muscle	O
force	O
did	O
not	O
change	O
significantly	O
over	O
the	O
study	O
interval	O
.	O
At	O
baseline,	O
dialysis	O
participants	O
reported	O
significantly	O
fewer	O
hours	O
per	O
week	O
of	O
total	O
and	O
moderate-to-high	O
impact	O
physical	O
activity,	O
vs	O
non-dialysis	O
CKD	O
participants	O
and	O
vs	O
reference	O
participants	O
-LRB-all	O
comparisons	O
p<0.01-RRB-	O
.	O
Reference	O
participants	O
reported	O
a	O
median	O
of	O
12.7	O
-LRB-IQR	O
8.1,	O
20.6-RRB-	O
total	O
hours	O
per	O
week	O
and	O
5.7	O
-LRB-IQR	O
3.0,	O
9.7-RRB-	O
moderate-to-high	O
impact	O
hours	O
per	O
week	O
.	O
In	O
both	O
CKD	O
groups	O
physical	O
activity	O
declined	O
over	O
the	O
study	O
interval	O
.	O
Assessment	O
of	O
the	O
Functional	O
Muscle	O
Bone	O
Unit	O
In	O
order	O
to	O
determine	O
if	O
changes	O
in	O
muscle	O
area	O
Z-scores	O
in	O
CKD	O
participants	O
were	O
associated	O
with	O
the	O
expected	O
changes	O
in	O
cortical	O
Z-scores,	O
i.e	O
the	O
functional	O
muscle-bone	O
unit,13	O
the	O
12	O
month	O
changes	O
in	O
cortical	O
area	O
Z-scores	O
were	O
compared	O
in	O
the	O
CKD	O
participants	O
and	O
the	O
269	O
reference	O
participants	O
enrolled	O
in	O
the	O
longitudinal	O
substudy	O
.	O
These	O
analyses	O
were	O
adjusted	O
for	O
baseline	O
muscle	O
area	O
and	O
baseline	O
cortical	O
area	O
Z-scores,	O
age	O
and	O
tibia	O
growth	O
.	O
Changes	O
in	O
cortical	O
area	O
Z-scores	O
were	O
positively	O
associated	O
with	O
changes	O
in	O
muscle	O
area	O
Z-scores	O
in	O
the	O
reference	O
participants	O
-LRB-p<0.001-RRB-;	O
however,	O
this	O
association	O
was	O
absent	O
in	O
CKD	O
participants	O
-LRB-interaction	O
p<0.001-RRB-	O
-LRB-Figure	O
2-RRB-	O
.	O
Discussion	O
This	O
is	O
the	O
first	O
study	O
to	O
examine	O
changes	O
in	O
trabecular	O
and	O
cortical	O
volumetric	O
BMD,	O
cortical	O
dimensions,	O
muscle	O
area	O
and	O
muscle	O
strength	O
in	O
childhood	O
CKD	O
.	O
Secondary	O
hyperparathyroidism	O
in	O
CKD	O
was	O
associated	O
with	O
greater	O
increases	O
in	O
trabecular	O
BMD	O
Z-scores	O
and	O
greater	O
declines	O
in	O
cortical	O
BMD	O
Z-scores	O
in	O
younger	O
participants	O
.	O
Cortical	O
BMD,	O
cortical	O
area,	O
and	O
periosteal	O
circumference	O
Z-scores	O
decreased	O
significantly	O
over	O
one	O
year	O
.	O
The	O
positive	O
association	O
between	O
changes	O
in	O
muscle	O
and	O
cortical	O
area	O
Z-scores	O
observed	O
in	O
reference	O
participants	O
was	O
absent	O
in	O
CKD	O
.	O
Prior	B-tomography
longitudinal	I-tomography
bone	I-tomography
imaging	I-tomography
studies	I-tomography
in	I-tomography
children	I-tomography
with	O
CKD	O
were	O
limited	O
to	O
DXA	B-tomography
and	I-tomography
quantitative	I-tomography
ultrasound	I-tomography
methods.3-6	I-tomography
These	I-tomography
studies	I-tomography
were	O
further	O
limited	O
by	O
small	O
sample	O
sizes	O
and	O
inadequate	O
reference	O
data	O
.	O
Longitudinal	O
studies	O
using	O
pQCT	O
in	O
CKD	O
are	O
limited	O
to	O
two	O
radius	O
studies	O
in	O
older	O
adults:	O
Obatake	O
et	O
al	O
reported	O
decreases	O
in	O
trabecular	O
and	O
cortical	O
BMD	O
over	O
one	O
year	O
in	O
53	O
pre-dialysis	O
patients	O
-LRB-mean	O
age	O
61	O
years-RRB-.14	O
Fujimore	O
et	O
al	O
reported	O
decreases	O
in	O
cortical	O
BMD	O
and	O
cortical	O
bone	O
area	O
over	O
two	O
years	O
in	O
53	O
hemodialysis	O
patients	O
-LRB-mean	O
age	O
67	O
years-RRB-.15	O
Given	O
the	O
absence	O
of	O
reference	O
participants,	O
it	O
is	O
not	O
known	O
if	O
these	O
changes	O
were	O
greater	O
than	O
expected	O
with	O
aging	O
.	O
The	O
association	O
between	O
hyperparathyroidism	O
and	O
increased	O
trabecular	O
BMD	O
in	O
younger	O
children	O
with	O
CKD	O
has	O
been	O
described	O
in	O
prior	O
cross-sectional	O
studies,2,	O
10,	O
16-19	O
and	O
confirmed	O
in	O
this	O
longitudinal	O
study	O
.	O
We	O
hypothesized	O
that	O
the	O
elevated	O
trabecular	O
BMD	O
in	O
the	O
younger	O
children	O
was	O
due	O
to	O
iPTH	O
and	O
CKD	O
effects	O
at	O
the	O
metaphysis,	O
with	O
impaired	O
resorption	O
of	O
the	O
dense	O
metaphyseal	O
spongiosa.20	O
Our	O
prior	O
cross-sectional	O
study	O
demonstrated	O
an	O
inverse	O
association	O
between	O
iPTH	O
levels	O
and	O
cortical	O
volumetric	O
BMD	O
across	O
all	O
ages;	O
however,	O
this	O
longitudinal	O
study	O
only	O
detected	O
this	O
association	O
in	O
younger	O
participants	O
.	O
The	O
study	O
by	O
Obatake	O
et	O
al	O
failed	O
to	O
show	O
an	O
association	O
between	O
iPTH	O
levels	O
and	O
changes	O
in	O
cortical	O
BMD	O
while	O
the	O
study	O
by	O
Fujimore	O
et	O
al	O
detected	O
an	O
inverse	O
association	O
in	O
males	O
only.14,	O
15	O
Periosteal	O
and	O
endosteal	O
circumference	O
both	O
increased	O
with	O
higher	O
mean	O
levels	O
of	O
iPTH	O
in	O
our	O
study	O
.	O
The	O
increase	O
in	O
periosteal	O
circumference	O
is	O
consistent	O
with	O
prior	O
human	O
and	O
animal	O
studies	O
of	O
PTH	O
therapy.21,	O
22	O
The	O
increase	O
in	O
endosteal	O
circumference	O
is	O
consistent	O
with	O
a	O
study	O
of	O
bone	O
biopsies	O
in	O
adult	O
dialysis	O
patients,	O
demonstrating	O
that	O
hyperparathyroidism	O
was	O
associated	O
with	O
endocortical	O
resorption.23	O
The	O
European	O
guidelines	O
advise	O
lower	O
target	O
PTH	O
levels,	O
compared	O
with	O
KDOQI	O
.	O
The	O
observation	O
that	O
PTH	O
levels	O
above	O
the	O
European	O
target	O
-LRB-but	O
within	O
the	O
KDOQI	O
target	O
range-RRB-	O
were	O
associated	O
with	O
changes	O
in	O
trabecular	O
and	O
cortical	O
BMD,	O
compared	O
with	O
participants	O
that	O
were	O
not	O
above	O
the	O
European	O
target	O
provides	O
preliminary	O
support	O
for	O
these	O
lower	O
targets.12	O
Prior	O
studies	O
have	O
shown	O
variable	O
results	O
with	O
different	O
PTH	O
assay	O
methods;	O
24	O
however,	O
our	O
study	O
used	O
the	O
same	O
assay	O
throughout	O
and	O
confirmed	O
the	O
results	O
using	O
the	O
bioactive	O
1-84	O
PTH	O
level	O
.	O
This	O
study	O
demonstrated	O
that	O
concurrent	O
rhGH	O
therapy	O
was	O
associated	O
with	O
preservation	O
of	O
section	O
modulus	O
Z-scores	O
and	O
greater	O
declines	O
in	O
fat	O
area	O
Z-scores	O
.	O
However,	O
the	O
results	O
must	O
be	O
interpreted	O
with	O
caution	O
given	O
the	O
small	O
number	O
of	O
participants	O
treated	O
with	O
rhGH	O
and	O
our	O
failure	O
to	O
detect	O
significant	O
associations	O
with	O
changes	O
in	O
periosteal	O
and	O
endosteal	O
circumference	O
or	O
muscle	O
area	O
Z-scores	O
.	O
To	O
our	O
knowledge	O
pediatric	O
CKD	O
BMD	O
studies	O
of	O
growth	O
hormone	O
therapy	O
are	O
limited	O
to	O
DXA	O
imaging	O
.	O
5,	O
6,	O
25-27	O
These	O
studies	O
yielded	O
conflicting	O
results,	O
likely	O
due	O
to	O
variable	O
reference	O
data,	O
and	O
adjustments	O
for	O
short	O
stature	O
and	O
intercurrent	O
growth	O
.	O
None	O
of	O
these	O
studies	O
examined	O
volumetric	O
BMD	O
or	O
cortical	O
dimensions	O
.	O
In	O
contrast,	O
a	O
radius	O
pQCT	O
study	O
by	O
Schweizer	O
et	O
al28,	O
in	O
prepubertal	O
children	O
with	O
growth	O
hormone	O
deficiency	O
demonstrated	O
that	O
cortical	O
total	O
area	O
-LRB-a	O
measure	O
of	O
periosteal	O
dimensions-RRB-	O
increased	O
significantly	O
relative	O
to	O
height	O
age;	O
marrow	O
area	O
-LRB-a	O
measure	O
of	O
endosteal	O
dimensions-RRB-	O
and	O
cortical	O
area	O
did	O
not	O
change	O
significantly	O
after	O
one	O
year	O
of	O
rhGH	O
therapy	O
.	O
This	O
is	O
consistent	O
with	O
our	O
observation	O
that	O
rhGH	O
was	O
associated	O
with	O
improvements	O
in	O
cortical	O
dimensions	O
.	O
Larger	O
controlled	O
studies	O
are	O
needed	O
to	O
establish	O
rhGH	O
effects	O
on	O
bone	O
accrual	O
in	O
CKD	O
.	O
The	O
longitudinal	O
data	O
in	O
our	O
pediatric	O
CKD	O
cohort	O
demonstrated	O
significant	O
and	O
worsening	O
cortical	O
area	O
deficits	O
over	O
one	O
year	O
.	O
Given	O
the	O
strong	O
association	O
between	O
cortical	O
bone	O
strength	O
and	O
muscle	O
mass	O
during	O
normal	O
growth	O
-LRB-Figure	O
2A-RRB-,	O
we	O
examined	O
the	O
associations	O
between	O
cortical	O
bone	O
and	O
muscle	O
area	O
.	O
The	O
positive	O
association	O
was	O
absent	O
in	O
CKD	O
-LRB-Figure	O
2B-RRB-	O
.	O
This	O
may	O
be	O
explained	O
by	O
lower	O
muscle	O
force	O
relative	O
to	O
muscle	O
area	O
in	O
CKD	O
13,	O
29	O
and	O
less	O
physical	O
activity.30,	O
31	O
Prior	O
studies	O
have	O
demonstrated	O
muscle	O
abnormalities	O
including	O
muscle	O
atrophy,	O
myopathy,	O
and	O
reduced	O
physical	O
functioning	O
in	O
pediatric	O
dialysis	O
patients.19,	O
32	O
Prior	O
pQCT	O
studies	O
in	O
adults	O
with	O
pre-dialysis	O
CKD33,	O
and	O
those	O
on	O
maintenance	O
hemodialysis34	O
demonstrated	O
that	O
decreased	O
cortical	O
thickness	O
and	O
BMD	O
were	O
significantly	O
associated	O
with	O
greater	O
odds	O
of	O
fracture	O
.	O
While	O
the	O
sample	O
size	O
is	O
inadequate	O
to	O
address	O
age,	O
sex,	O
and	O
skeletal	O
site	O
specific	O
fracture	O
rates,	O
it	O
is	O
noteworthy	O
that	O
6	O
of	O
103	O
CKD	O
participants	O
had	O
a	O
fracture	O
during	O
the	O
study	O
interval	O
.	O
This	O
rate	O
is	O
higher	O
than	O
observed	O
in	O
healthy	O
pediatric	O
population-based	O
studies	O
at	O
any	O
age	O
in	O
males	O
or	O
females.35	O
The	O
wide	O
spectrum	O
of	O
underlying	O
renal	O
disease	O
and	O
duration,	O
and	O
differences	O
in	O
participant	O
treatment	O
characteristics	O
is	O
a	O
significant	O
limitation	O
of	O
this	O
study	O
.	O
The	O
study	O
included	O
participants	O
with	O
conditions	O
and	O
medications	O
that	O
can	O
impact	O
bone	O
health,	O
including	O
glucocorticoids,	O
calcineurin	O
inhibitors	O
and	O
rhGH	O
.	O
Furthermore,	O
the	O
majority	O
of	O
dialysis	O
participants	O
had	O
a	O
history	O
of	O
prior	O
allograft	O
failure	O
.	O
The	O
subgroup	O
analyses	O
had	O
limited	O
power	O
and	O
we	O
were	O
unable	O
to	O
define	O
associations	O
between	O
disease	O
characteristics	O
and	O
changes	O
in	O
bone	O
outcomes	O
.	O
Therefore,	O
the	O
results	O
should	O
be	O
considered	O
with	O
caution	O
and	O
used	O
to	O
generate	O
hypotheses	O
for	O
future	O
studies	O
.	O
A	O
second	O
limitation	O
is	O
the	O
lack	O
of	O
bone	O
biopsy	O
data,	O
precluding	O
measures	O
of	O
trabecular	O
bone	O
microarchitecture,	O
turnover	O
or	O
mineralization	O
.	O
The	O
term	O
CKD-Mineral	O
and	O
Bone	O
Disorder	O
-LRB-CKD-MBD-RRB-	O
describes	O
a	O
broad	O
systemic	O
disorder	O
of	O
mineral	O
and	O
bone	O
metabolism,	O
as	O
well	O
as	O
vascular	O
and	O
soft-tissue	O
calcification.36	O
We	O
were	O
also	O
unable	O
to	O
address	O
extra-skeletal	O
calcification	O
.	O
A	O
final	O
limitation	O
is	O
the	O
lack	O
of	O
measures	O
of	O
FGF-23	O
.	O
However,	O
a	O
recent	O
bone	O
biopsy	O
study	O
reported	O
that	O
FGF-23	O
levels	O
were	O
not	O
associated	O
with	O
defective	O
mineralization.37	O
Given	O
that	O
a	O
recent	O
biopsy	O
study	O
in	O
52	O
children	O
with	O
pre-dialysis	O
CKD	O
reported	O
evidence	O
of	O
defective	O
mineralization	O
in	O
29%	O
of	O
patients	O
with	O
stage	O
2,	O
42%	O
with	O
stage	O
3,	O
and	O
79%	O
with	O
stage	O
4/5	O
CKD,	O
future	O
studies	B-tomography
comparing	I-tomography
QCT	I-tomography
scans	I-tomography
and	I-tomography
bone	I-tomography
biopsies	I-tomography
are	O
needed	O
to	O
determine	O
the	O
sensitivity	O
of	O
QCT	O
to	O
identify	O
mineralization	O
defects.37	O
The	O
study	O
design	O
has	O
multiple	O
important	O
strengths	O
.	O
It	O
is	O
the	O
largest	O
longitudinal	O
bone	O
study	O
of	O
childhood	O
onset	O
CKD	O
and	O
the	O
first	O
to	O
use	O
pQCT	O
to	O
quantify	O
changes	O
in	O
bone	O
and	O
muscle	O
.	O
It	O
included	O
a	O
large	O
robust	O
longitudinal	O
reference	O
sample	O
permitting	O
adjustment	O
for	O
age,	O
sex,	O
race,	O
tibia	O
length	O
and	O
muscle	O
area	O
in	O
the	O
assessment	O
of	O
bone	O
outcomes	O
.	O
Furthermore	O
the	O
use	O
of	O
Z-scores	O
for	O
volumetric	O
BMD,	O
cortical	O
dimensions,	O
and	O
muscle	O
deficits	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
clinical	O
magnitude	O
of	O
the	O
deficits	O
.	O
We	O
recently	O
compared	O
DXA	O
and	O
pQCT	O
results	O
in	O
a	O
cross-sectional	O
analyses	O
of	O
88	O
participants.38	O
While	O
pQCT	O
measures	O
of	O
trabecular	O
BMD	O
were	O
associated	O
with	O
DXA	O
measures	O
of	O
lumbar	O
spine	O
BMD	O
-LRB-R2=0.13-RRB-	O
and	O
pQCT	O
measures	O
of	O
cortical	O
bone	O
mineral	O
content	O
were	O
associated	O
with	O
DXA	O
whole	O
body	O
bone	O
mineral	O
content	O
-LRB-R2=0.41-RRB-,	O
DXA	O
measures	O
were	O
not	O
associated	O
with	O
iPTH	O
levels	O
.	O
Therefore,	O
the	O
clinical	O
utility	O
of	O
DXA	O
remains	O
unproven	O
.	O
In	O
summary,	O
our	O
data	O
demonstrated	O
that	O
children	O
and	O
adolescents	O
with	O
CKD	O
have	O
progressive	O
declines	O
in	O
cortical	O
bone	O
accrual	O
at	O
one	O
year	O
follow-up,	O
partially	O
related	O
to	O
hyperparathyroidism	O
and	O
muscle	O
deficits	O
.	O
Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
fracture	O
implications	O
of	O
these	O
findings,	O
and	O
to	O
identify	O
therapies	O
to	O
enhance	O
bone	O
quality	O
in	O
children	O
with	O
CKD	O
.	O
Materials	O
and	O
Methods	O
Study	O
participants	O
The	O
study	O
cohort	O
consisted	O
of	O
children	O
and	O
adolescents	O
aged	O
5-21	O
years	O
with	O
CKD	O
-LRB-baseline	O
eGFR	O
<	O
90	O
ml/min/1.73m2-RRB-	O
enrolled	O
in	O
a	O
larger	O
study	O
of	O
bone	O
health	O
in	O
CKD	O
at	O
Children's	O
Hospital	O
of	O
Philadelphia	O
-LRB-CHOP-RRB-	O
and	O
Cincinnati	O
Children's	O
Hospital	O
and	O
Medical	O
Center	O
-LRB-CCHMC-RRB-.1,	O
2,	O
38-40	O
Patients	O
were	O
ineligible	O
for	O
this	O
study	O
if	O
they	O
had	O
a	O
history	O
of	O
chronic	O
conditions	O
unrelated	O
to	O
CKD	O
that	O
may	O
impact	O
bone	O
health	O
or	O
had	O
a	O
functioning	O
renal	O
allograft	O
.	O
This	O
study	O
population	O
was	O
compared	O
to	O
a	O
reference	O
population	O
of	O
903	O
healthy	O
children	O
and	O
adolescents	O
from	O
CHOP	O
recruited	O
from	O
general	O
pediatric	O
practices	O
in	O
the	O
greater	O
Philadelphia	O
area.2,	O
10	O
Reference	O
participants	O
were	O
excluded	O
for	O
medical	O
history	O
of	O
illness	O
or	O
medications	O
that	O
could	O
affect	O
growth	O
and	O
development	O
.	O
A	O
total	O
of	O
269	O
completed	O
a	O
12	O
month	O
visit	O
in	O
a	O
longitudinal	O
substudy.10,	O
41	O
Study	O
approval	O
was	O
obtained	O
from	O
the	O
Institutional	O
Review	O
Boards	O
at	O
CHOP	O
and	O
CCHMC	O
.	O
Informed	O
consent	O
was	O
obtained	O
directly	O
from	O
study	O
patients	O
18	O
years	O
of	O
age,	O
and	O
assent	O
as	O
well	O
as	O
parental	O
consent	O
in	O
those	O
<	O
18	O
years	O
of	O
age	O
.	O
Anthropometry,	O
Sexual	O
Maturity	O
and	O
Race	O
Height	O
was	O
measured	O
using	O
a	O
stadiometer	O
-LRB-Holtain,	O
Crymych,	O
UK-RRB-	O
and	O
weight	O
with	O
a	O
digital	O
scale	O
-LRB-Scaletronix,	O
White	O
Plains,	O
New	O
York-RRB-	O
.	O
Tibia	O
length	O
was	O
measured	O
with	O
a	O
segmometer	O
.	O
Pubertal	O
development	O
was	O
assessed	O
using	O
a	O
self-assessment	O
questionnaire	O
and	O
classified	O
according	O
to	O
Tanner	O
stage.42,	O
43	O
Participant's	O
race	O
was	O
categorized	O
by	O
parents	O
or	O
the	O
participant	O
according	O
to	O
the	O
National	O
Institutes	O
of	O
Health	O
categories	O
.	O
Physical	O
Activity	O
Questionnaire	O
The	O
physical	O
activity	O
questionnaire	O
was	O
designed	O
to	O
assess	O
biomechanical	O
impact.10,	O
44,	O
45	O
The	O
questionnaire	O
was	O
introduced	O
mid-study	O
in	O
the	O
reference	O
participants	O
and	O
completed	O
in	O
401	O
participants	O
.	O
CKD	O
Disease	O
Characteristics	O
and	O
Medications	O
Medical	O
charts	O
were	O
reviewed	O
for	O
the	O
date	O
of	O
diagnosis,	O
cause	O
of	O
underlying	O
renal	O
disease,	O
fracture	O
history,	O
medications,	O
and	O
dialysis	O
and	O
transplant	O
history	O
.	O
Underlying	O
renal	O
disease	O
was	O
categorized	O
as	O
congenital	O
anomalies	O
of	O
the	O
kidney	O
and	O
urinary	O
tract	O
-LRB-CAKUT-RRB-,	O
FSGS,	O
systemic	O
inflammatory	O
disease	O
and	O
other	O
.	O
All	O
fracture	O
events	O
during	O
the	O
study	O
were	O
confirmed	O
by	O
review	O
of	O
radiology	O
reports	O
.	O
Peripheral	O
Quantitative	O
Computed	O
Tomography	O
Bone,	O
muscle	O
and	O
fat	O
measures	O
were	O
obtained	O
in	O
the	O
left	O
tibia	O
using	O
a	O
Stratec	O
XCT2000	O
pQCT	O
device	O
-LRB-Orthometrix,	O
White	O
Plains,	O
NY-RRB-	O
.	O
Scan	O
parameters,	O
software	O
and	O
calibration	O
procedures	O
have	O
been	O
described.2,	O
10	O
Bone	O
measurements	O
were	O
obtained	O
at	O
the	O
3%	O
metaphyseal	O
site	O
for	O
trabecular	O
volumetric	O
BMD	O
-LRB-mg/cm3-RRB-	O
and	O
at	O
the	O
38%	O
diaphyseal	O
site	O
for	O
cortical	O
volumetric	O
BMD,	O
-LRB-mg/cm3-RRB-,	O
periosteal	O
and	O
endosteal	O
circumference	O
-LRB-mm-RRB-,	O
cortical	O
cross	O
sectional	O
area	O
-LRB-mm2-RRB-,	O
and	O
polar	O
section	O
modulus	O
-LRB-mm3-RRB-	O
.	O
Fat	O
and	O
muscle	O
area	O
-LRB-mm3-RRB-	O
were	O
assessed	O
66%	O
proximal	O
to	O
the	O
distal	O
physis	O
.	O
The	O
manufacturer's	O
hydroxyapatite	O
phantom	O
was	O
scanned	O
daily	O
.	O
In	O
our	O
laboratory,	O
the	O
coefficient	O
of	O
variation	O
-LRB-CV-RRB-	O
ranged	O
from	O
0.5	O
to	O
1.6%	O
for	O
pQCT	O
outcomes	O
in	O
children	O
and	O
adolescents	O
.	O
Measurement	O
of	O
Muscle	O
Force	O
Muscle	O
force	O
in	O
ankle	O
dorsiflexion	O
was	O
assessed	O
using	O
isometric	O
dynamometry	O
-LRB-Biodex	O
Medical	O
Systems,	O
Inc,	O
Shirley,	O
NY-RRB-.46	O
The	O
Biodex	O
measures	O
were	O
performed	O
in	O
280	O
reference	O
participants	O
and	O
in	O
the	O
CKD	O
participants	O
at	O
the	O
baseline	O
and	O
12	O
month	O
follow-up	O
visit	O
at	O
CHOP	O
only	O
.	O
Laboratory	O
Measurements	O
Non-fasting	O
blood	O
chemistries	O
and	O
iPTH	O
were	O
measured	O
at	O
baseline,	O
6	O
and	O
12	O
months	O
in	O
non-dialysis	O
participants	O
and	O
baseline,	O
3,	O
6,	O
and	O
12	O
months	O
in	O
dialysis	O
participants	O
.	O
Serum	O
bicarbonate	O
-LRB-mmol/L-RRB-,	O
calcium	O
-LRB-mg/dL-RRB-,	O
phosphorus	O
-LRB-mg/dL-RRB-,	O
and	O
albumin	O
-LRB-g/dL-RRB-	O
concentrations	O
were	O
measured	O
in	O
clinical	O
laboratories	O
using	O
standard	O
methods	O
and	O
calcium	O
levels	O
were	O
adjusted	O
for	O
albumin	O
levels.47	O
Plasma	O
PTH	O
-LRB-pg/ml-RRB-	O
was	O
measured	O
using	O
two	O
different	O
immunoradiometric	O
assays	O
-LRB-IRMA-RRB-	O
with	O
I125I-	O
labeled	O
tracer	O
-LRB-Scantibodies	O
Clinical	O
Laboratory,	O
Santee,	O
CA,	O
USA-RRB-	O
.	O
The	O
traditional	O
second	O
generation	O
IRMA	O
measured	O
iPTH	O
.	O
The	O
third	O
generation	O
assay	O
used	O
a	O
specific	O
polyclonal	O
PTH	O
antibody	O
directed	O
against	O
the	O
most	O
N-terminal	O
PTH	O
region	O
as	O
tracer	O
antibody	O
in	O
order	O
to	O
measure	O
the	O
bioactive	O
1-84	O
PTH	O
molecule	O
.	O
The	O
intra-assay	O
CV	O
for	O
the	O
intact	O
and	O
bioactive	O
PTH	O
assays	O
were	O
3	O
to	O
5%	O
and	O
3	O
to	O
10%	O
respectively	O
.	O
48	O
Serum	O
creatinine	O
-LRB-mg/dL-RRB-	O
was	O
measured	O
by	O
spectrophotometric	O
enzymatic	O
assay	O
-LRB-Vitros,	O
Johnson	O
&	O
Johnson	O
Co,	O
Rochester,	O
NY-RRB-	O
with	O
a	O
CV	O
of	O
1%	O
to	O
5%	O
.	O
Estimated	O
GFR	O
-LRB-ml/min/1.73m2-RRB-	O
was	O
calculated	O
based	O
on	O
height	O
and	O
serum	O
creatinine	O
using	O
the	O
pediatric	O
estimating	O
equation	O
from	O
the	O
Chronic	O
Kidney	O
Disease	O
in	O
Children	O
prospective	O
cohort	O
study	O
49	O
.	O
CKD	O
stage	O
was	O
classified	O
according	O
to	O
National	O
Kidney	O
Foundation	O
guidelines.50	O
Dialysis	O
patients	O
were	O
assigned	O
an	O
eGFR	O
of	O
7.5	O
ml/min/1.73m2	O
for	O
models	O
examining	O
baseline	O
eGFR	O
as	O
a	O
continuous	O
variable,	O
and	O
for	O
calculating	O
change	O
in	O
eGFR	O
in	O
the	O
two	O
participants	O
that	O
started	O
dialysis	O
during	O
the	O
study	O
.	O
Statistical	O
Analysis	O
Analysis	O
were	O
performed	O
using	O
Stata	O
11.0	O
-LRB-Stata	O
Corp.,	O
College	O
Station,	O
TX,	O
USA-RRB-	O
.	O
A	O
p	O
value	O
<	O
0.05	O
was	O
considered	O
statistically	O
significant	O
and	O
two	O
sided	O
tests	O
of	O
hypotheses	O
were	O
used	O
throughout	O
.	O
Continuous	O
variables	O
were	O
expressed	O
as	O
means	O
SD	O
or	O
median	O
-LRB-IQR-RRB-	O
if	O
not	O
normally	O
distributed	O
.	O
Group	O
differences	O
were	O
assessed	O
using	O
Student's	O
t	O
test	O
or	O
the	O
Wilcoxon	O
rank	O
sum	O
test	O
.	O
Changes	O
within	O
the	O
CKD	O
patients	O
were	O
tested	O
using	O
the	O
paired	O
t-test	O
or	O
the	O
Wilcoxon	O
signed	O
rank	O
test	O
.	O
Differences	O
in	O
proportions	O
were	O
tested	O
using	O
the	O
chi-square	O
test	O
.	O
Correlations	O
between	O
continuous	O
variables	O
were	O
assessed	O
by	O
Pearson	O
or	O
Spearman's	O
correlations	O
.	O
Although	O
this	O
study	O
included	O
multiple	O
comparison,	O
we	O
did	O
not	O
apply	O
a	O
Bonferroni	O
correction	O
because	O
this	O
assumes	O
the	O
multiple	O
outcomes	O
are	O
independent.51	O
The	O
majority	O
of	O
bone	O
and	O
muscle	O
Z-score	O
were	O
highly	O
correlated	O
.	O
Rather,	O
we	O
evaluated	O
the	O
results	O
for	O
internal	O
consistency	O
and	O
interpreted	O
isolated	O
results	O
with	O
caution	O
.	O
Age-	O
and	O
sex-	O
specific	O
height	O
and	O
BMI	O
Z-scores	O
were	O
calculated	O
using	O
national	O
data	O
.	O
52	O
All	O
PTH	O
levels	O
were	O
log	O
transformed	O
and	O
a	O
mean	O
value	O
created	O
for	O
each	O
individual	O
over	O
the	O
study	O
interval,	O
and	O
used	O
in	O
the	O
longitudinal	O
models	O
.	O
The	O
pQCT	O
outcomes	O
were	O
converted	O
to	O
race	O
and	O
sex	O
specific	O
Z-scores	O
using	O
the	O
LMS	O
method	O
based	O
on	O
the	O
reference	O
participants,	O
as	O
described.2,	O
10,	O
53,	O
54	O
This	O
method	O
accounts	O
for	O
the	O
non-linearity,	O
heteroscedasticity	O
and	O
skew	O
of	O
bone	O
data	O
during	O
growth.55,	O
56	O
Trabecular	O
and	O
cortical	O
BMD	O
were	O
assessed	O
relative	O
to	O
age	O
.	O
Cortical	O
geometry,	O
muscle	O
and	O
fat	O
outcomes	O
were	O
correlated	O
with	O
tibia	O
length	O
-LRB-all	O
p<0.0001-RRB-;	O
therefore,	O
the	O
Z-scores	O
were	O
generated	O
relative	O
to	O
tibia	O
length	O
and	O
further	O
adjusted	O
for	O
age	O
and	O
tibia	O
length	O
using	O
linear	O
regression	O
analyses	O
.	O
Changes	O
in	O
pQCT	O
Z-scores	O
within	O
the	O
CKD	O
participants	O
were	O
annualized	O
-LRB-change	O
per	O
12	O
months-RRB-	O
and	O
assessed	O
using	O
multivariate	O
regression	O
models	O
.	O
Given	O
the	O
differences	O
in	O
disease	O
and	O
participant	O
characteristics	O
in	O
the	O
non-dialysis	O
and	O
dialysis	O
participants,	O
we	O
stratified	O
the	O
annualized	O
changes	O
in	O
bone	O
outcomes	O
-LRB-Table	O
3-RRB-	O
.	O
However,	O
the	O
associations	O
between	O
changes	O
in	O
bone	O
outcomes	O
and	O
exposure	O
variables	O
did	O
not	O
differ	O
between	O
the	O
non-dialysis	O
and	O
dialysis	O
participants	O
.	O
Therefore,	O
multivariate	O
regression	O
models	O
of	O
changes	O
examined	O
the	O
entire	O
cohort	O
together	O
.	O
The	O
following	O
covariates	O
were	O
tested	O
for	O
each	O
pQCT	O
outcome-	O
baseline	O
outcome	O
Z-score,	O
study	O
location,	O
age,	O
sex,	O
race,	O
Tanner	O
stage,	O
disease	O
characteristics,	O
concurrent	O
medications,	O
and	O
baseline	O
and	O
change	O
values	O
for	O
eGFR	O
and	O
physical	O
activity	O
.	O
Bone	O
models	O
also	O
included	O
mean	O
iPTH	O
levels	O
.	O
All	O
of	O
the	O
models	O
that	O
included	O
the	O
iPTH	O
covariate	O
were	O
repeated	O
using	O
1-84	O
or	O
7-84	O
PTH	O
levels,	O
yielding	O
the	O
same	O
results	O
-LRB-data	O
not	O
shown-RRB-	O
.	O
The	O
correlations	O
between	O
iPTH,	O
1-84	O
PTH	O
and	O
7-84	O
PTH	O
exceeded	O
0.98;	O
therefore	O
it	O
was	O
not	O
possible	O
to	O
assess	O
independent	O
associations	O
.	O
The	O
1-84/7-84	O
ratio	O
was	O
not	O
significant	O
in	O
any	O
longitudinal	O
models	O
.	O
Secondary	O
analyses	O
were	O
performed	O
comparing	O
pQCT	O
Z-scores	O
in	O
participants	O
that	O
were	O
above	O
the	O
European	O
iPTH	O
target	O
but	O
within	O
KDOQI	O
target	O
range,	O
vs	O
those	O
without	O
elevated	O
iPTH	O
by	O
either	O
target	O
.	O
The	O
associations	O
between	O
changes	O
in	O
muscle	O
and	O
cortical	O
area	O
Z-scores	O
were	O
compared	O
in	O
the	O
CKD	O
participants	O
and	O
the	O
longitudinal	O
subset	O
of	O
reference	O
participants	O
using	O
multivariable	O
regression	O
analysis	O
.	O
Models	O
for	O
peak	O
muscle	O
torque	O
were	O
compared	O
in	O
the	O
CKD	O
and	O
reference	O
participants	O
adjusted	O
for	O
age,	O
sex,	O
race,	O
tibia	O
length	O
and	O
muscle	O
area.57	O
.	O
A	O
34-year-old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
of	O
recently	O
aggravated	O
right	O
heart	O
failure	O
without	O
angina	O
for	O
5	O
months	O
.	O
When	O
she	O
was	O
25	O
years	O
old,	O
patch	O
repair	O
with	O
Polytetrafluoroethylene	O
-LRB-PTFE-RRB-	O
was	O
performed	O
for	O
the	O
secondum	O
type	O
of	O
atrial	O
septal	O
defect	O
-LRB-ASD-RRB-	O
with	O
moderate	O
pulmonary	O
hypertension	O
.	O
The	O
chest	O
PA,	O
echocardiography	O
and	O
cardiac	O
catheterization	O
at	O
current	O
admission	O
revealed	O
Eisenmenger	O
syndrome	O
without	O
intracardiac	O
shunt	O
.	O
Chest	O
CT	O
scan	O
with	O
contrast	O
revealed	O
markedly	O
dilated	O
pulmonary	O
trunk,	O
both	O
pulmonary	O
arteries	O
and	O
concave	O
disfigurement	O
of	O
the	O
left	O
side	O
of	O
the	O
ascending	O
aorta	O
suggesting	O
extrinsic	O
compression,	O
as	O
well	O
as	O
total	O
occlusion	O
of	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
that	O
was	O
retrogradly	O
filled	O
with	O
collateral	O
circulation	O
from	O
the	O
right	O
coronary	O
artery	O
.	O
The	O
coronary	O
angiography	O
showed	O
normal	O
right	O
coronary	O
artery	O
and	O
the	O
collaterals	O
that	O
come	O
out	O
from	O
the	O
conus	O
branch	O
to	O
the	O
mid-left	O
anterior	O
descending	O
artery	O
-LRB-LAD-RRB-	O
and	O
that	O
from	O
distal	O
right	O
coronary	O
artery	O
to	O
the	O
left	O
circumflex	O
artery	O
-LRB-LCX-RRB-	O
and	O
to	O
the	O
distal	O
LAD,	O
respectively	O
.	O
On	O
aortography,	O
the	O
left	O
main	O
coronary	O
artery	O
was	O
not	O
visualized	O
with	O
no	O
stump,	O
suggestive	O
of	O
total	O
occlusion	O
of	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
.	O
From	O
our	O
experience,	O
it	O
is	O
possible	O
to	O
say	O
that	O
the	O
occlusion	O
of	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
can	O
be	O
induced	O
by	O
the	O
dilated	O
pulmonary	O
artery	O
trunk	O
due	O
to	O
ASD	O
with	O
pulmonary	O
hypertension	O
and	O
that,	O
if	O
the	O
ASD	O
closure	O
was	O
too	O
late,	O
the	O
narrowing	O
or	O
obstruction	O
of	O
the	O
left	O
coronary	O
artery	O
could	O
not	O
be	O
resolved	O
even	O
after	O
operation	O
owing	O
to	O
irreversible	O
pulmonary	O
hypertension	O
.	O
INTRODUCTION	O
Atrial	O
septal	O
defect	O
in	O
the	O
middle-aged	O
and	O
elderly,	O
which	O
is	O
associated	O
with	O
dilated	O
main	O
pulmonary	O
artery,	O
usually	O
induces	O
progressive	O
pulmonary	O
hypertension	O
in	O
cases	O
of	O
un-correction	O
or	O
delayed	O
corrective	O
surgery13-RRB-	O
.	O
Furthermore,	O
the	O
progressive	O
pulmonary	O
hypertension	O
is	O
associated	O
with	O
hemodynamic	O
compromise	O
of	O
the	O
left	O
ventricle	O
and	O
sudden	O
cardiac	O
death	O
due	O
to	O
the	O
collapse	O
of	O
systemic	O
circulation	O
.	O
However,	O
the	O
causes	O
of	O
sudden	O
death	O
in	O
the	O
patient	O
with	O
severe	O
pulmonary	O
hypertension	O
have	O
remained	O
uncertain	O
.	O
Among	O
the	O
causes	O
of	O
death,	O
the	O
failure	O
of	O
coronary	O
circulation	O
might	O
be	O
one	O
of	O
the	O
causes	O
.	O
In	O
this	O
case,	O
we	O
reviewed	O
total	O
occlusion	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
caused	O
by	O
extrinsic	O
compression	O
of	O
the	O
markedly	O
dilated	O
main	O
pulmonary	O
trunk47-RRB-	O
that	O
was	O
induced	O
by	O
progressive	O
pulmonary	O
hypertension	O
due	O
to	O
delayed	O
closure	O
of	O
the	O
atrial	O
septal	O
defect	O
.	O
CASE	O
A	O
34-year-old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
of	O
recently	O
aggravated	O
dyspnea,	O
general	O
edema	O
and	O
abdominal	O
distension	O
for	O
5	O
months	O
.	O
In	O
her	O
past,	O
she	O
had	O
no	O
history	O
of	O
Kawasaki	O
disease	O
during	O
childhood	O
.	O
However,	O
nine	O
years	O
before	O
admission,	O
patch	O
repair	O
with	O
PTFE	O
was	O
performed	O
for	O
the	O
secondum	O
type	O
of	O
atrial	O
septal	O
defect	O
-LRB-ASD-RRB-	O
.	O
Thereafter,	O
she	O
had	O
been	O
managed	O
for	O
pulmonary	O
hypertension	O
and	O
aggravating	O
right	O
heart	O
failure	O
.	O
The	O
preoperative	O
values	O
collected	O
from	O
her	O
past	O
medical	O
records	O
of	O
the	O
previous	O
hospital	O
included	O
pulmonary/systolic	O
flow	O
ratio	O
-LRB-Qp/Qs-RRB-	O
of	O
2:1,	O
pulmonary/systolic	O
resistance	O
ratio	O
-LRB-Rp/Rs-RRB-	O
of	O
0.35,	O
pulmonary	O
arterial	O
systolic	O
pressure	O
-LRB-PASP-RRB-	O
of	O
51	O
mmHg	O
and	O
the	O
diameter	O
of	O
main	O
pulmonary	O
artery	O
of	O
40	O
mm,	O
which	O
were	O
suggestive	O
of	O
significant	O
left	O
to	O
right	O
shunt	O
with	O
moderate	O
pulmonary	O
hypertension,	O
and	O
normal	O
coronary	O
artery	O
.	O
As	O
the	O
PASP	O
during	O
the	O
postoperative	O
care	O
was	O
not	O
decreased	O
to	O
the	O
normal	O
range,	O
the	O
doctor	O
who	O
operated	O
on	O
the	O
patient	O
cautioned	O
and	O
wrote	O
on	O
her	O
record	O
of	O
the	O
possibility	O
of	O
progressing	O
pulmonary	O
hypertension	O
.	O
On	O
admission,	O
blood	O
pressure	O
and	O
pulse	O
rate	O
were	O
110/70	O
mmHg	O
and	O
85	O
beats	O
per	O
minute,	O
respectively	O
.	O
On	O
physical	O
examination,	O
there	O
were	O
engorged	O
neck	O
vein,	O
soft	O
abdominal	O
distension,	O
palpable	O
liver,	O
and	O
pretibial	O
pitting	O
edema	O
.	O
Systolic	O
murmur	O
of	O
grade	O
III/VI	O
was	O
auscultated	O
from	O
her	O
lower	O
sternal	O
border	O
.	O
The	O
arterial	O
blood	O
gas	O
analysis	O
showed	O
pO2	O
of	O
77.4	O
mmHg,	O
pCo2	O
of	O
31.2	O
mmHg	O
under	O
the	O
room	O
air	O
.	O
The	O
rheumatoid	O
factor	O
-LRB-RF-RRB-	O
and	O
VDRL	O
for	O
syphilis	O
were	O
both	O
negative	O
.	O
The	O
electrocardiogram	O
revealed	O
normal	O
sinus	O
rhythm	O
with	O
incomplete	O
right	O
bundle	O
branch	O
block	O
and	O
biventricular	O
hypertrophy	O
.	O
The	O
chest	O
PA	O
showed	O
markedly	O
enlarged	O
cardiac	O
size	O
with	O
prominently	O
dilated	O
main	O
pulmonary	O
artery	O
and	O
centralization	O
of	O
pulmonary	O
hilum,	O
suggesting	O
pulmonary	O
arterial	O
hypertension	O
-LRB-Figure	O
1-RRB-	O
.	O
Echocardiogram	O
with	O
Doppler	O
study	O
demonstrated	O
right	O
ventricular	O
hypertrophy,	O
D-shape	O
left	O
ventricle,	O
as	O
well	O
as	O
severe	O
pulmonary	O
and	O
tricuspid	O
regurgitation,	O
which	O
corresponded	O
to	O
right	O
ventricular	O
systolic	O
pressure	O
of	O
117	O
mmHg	O
.	O
However,	O
there	O
was	O
no	O
intracardiac	O
shunt	O
remained	O
on	O
color	O
interrogation	O
.	O
Moreover,	O
serial	O
echocardiographic	O
evaluation	O
had	O
revealed	O
the	O
progression	O
of	O
pulmonary	O
hypertension	O
after	O
delivery	O
of	O
her	O
baby	O
.	O
A	O
diagnosis	O
of	O
Eisenmenger	O
syndrome	O
was	O
made	O
.	O
The	O
base-line	O
study	O
for	O
heart-lung	O
transplantation,	O
including	O
chest	O
computed	O
tomography	O
-LRB-CT-RRB-,	O
cardiac	O
catheterization	O
and	O
coronary	O
angiography	O
were	O
undertaken	O
.	O
Chest	O
CT	O
scan	O
with	O
contrast	O
revealed	O
markedly	O
dilated	O
pulmonary	O
trunk	O
and	O
both	O
pulmonary	O
arteries	O
-LRB-Figure	O
2A-RRB-,	O
a	O
concave	O
disfigurement	O
of	O
the	O
left	O
side	O
of	O
the	O
ascending	O
aorta	O
and	O
nearly	O
total	O
occlusion	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
that	O
was	O
retrogradly	O
filled	O
with	O
collateral	O
circulation	O
from	O
the	O
right	O
coronary	O
artery	O
-LRB-Figure	O
2B-RRB-	O
.	O
That	O
was	O
suggestive	O
of	O
compression	O
of	O
the	O
left	O
side	O
of	O
the	O
aorta	O
and	O
the	O
left	O
main	O
coronary	O
artery	O
together	O
by	O
the	O
pulmonary	O
trunk	O
passing	O
by	O
the	O
ascending	O
aortas	O
left	O
side	O
.	O
Cardiac	O
catheterization	O
revealed	O
PASP	O
of	O
105	O
mmHg,	O
Qp/Qs	O
of	O
1	O
and	O
Rp/Rs	O
of	O
1.4	O
-LRB-Figure	O
3-RRB-,	O
which	O
mean	O
no	O
remaining	O
shunt	O
but	O
much	O
aggravated	O
pulmonary	O
hypertension	O
compatible	O
with	O
Eisenmenger	O
syndrome	O
compared	O
with	O
preoperative	O
data	O
.	O
The	O
coronary	O
angiography	O
showed	O
normal	O
right	O
coronary	O
artery	O
and	O
the	O
collaterals	O
that	O
came	O
out	O
from	O
the	O
conus	O
branch	O
to	O
mid-left	O
anterior	O
descending	O
artery	O
-LRB-LAD-RRB-	O
and	O
that	O
from	O
the	O
distal	O
right	O
coronary	O
artery	O
to	O
the	O
left	O
circumflex	O
artery	O
-LRB-LCX-RRB-	O
and	O
to	O
the	O
distal	O
LAD,	O
respectively	O
-LRB-Figure	O
4,	O
5-RRB-	O
.	O
Engagement	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
with	O
the	O
diagnostic	O
coronary	O
catheter	O
was	O
not	O
available	O
.	O
On	O
aortography,	O
the	O
left	O
main	O
coronary	O
artery	O
was	O
not	O
visualized	O
with	O
no	O
stump,	O
suggesting	O
total	O
occlusion	O
of	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
-LRB-Figure	O
6-RRB-	O
.	O
There	O
was	O
no	O
other	O
luminal	O
lesion	O
in	O
the	O
remaining	O
part	O
of	O
the	O
coronary	O
artery	O
system	O
and	O
the	O
thoracic	O
as	O
well	O
as	O
the	O
abdominal	O
aorta	O
.	O
DISCUSSION	O
Some	O
adults	O
with	O
congenital	O
heart	O
disease	O
have	O
associated	O
ischemic	O
heart	O
disease3,	O
8-RRB-	O
.	O
On	O
the	O
other	O
hand,	O
atherosclerosis9-RRB-,	O
syphilis10-RRB-,	O
aortitis11,	O
12-RRB-	O
and	O
congenital	O
anomalies	O
of	O
the	O
coronary	O
artery1314-RRB-	O
are	O
widely-known	O
causes	O
of	O
stenosis	O
of	O
the	O
left	O
main	O
coronary	O
trunk	O
.	O
Compression	O
of	O
the	O
left	O
main	O
coronary	O
trunk	O
has	O
not	O
been	O
widely	O
known	O
.	O
However,	O
in	O
1957,	O
Corday,	O
et	O
al.4-RRB-	O
first	O
pointed	O
out	O
that	O
the	O
distended	O
main	O
pulmonary	O
artery	O
easily	O
compressed	O
the	O
left	O
main	O
coronary	O
trunk	O
because	O
of	O
the	O
spatial	O
position	O
of	O
the	O
proximal	O
part	O
of	O
the	O
left	O
coronary	O
artery	O
closed	O
to	O
the	O
main	O
pulmonary	O
artery	O
.	O
Schaffer,	O
et	O
al.5-RRB-	O
tried	O
to	O
prove	O
the	O
correlation	O
between	O
pulmonary	O
pressure	O
and	O
coronary	O
flow	O
at	O
autopsy	O
which,	O
however,	O
was	O
unsuccessful	O
because	O
the	O
main	O
pulmonary	O
artery	O
of	O
the	O
autopsied	O
heart	O
was	O
not	O
sufficiently	O
dilated	O
.	O
Mitsudo	O
et	O
al.6-RRB-	O
first	O
reported	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
ASD	O
that	O
was	O
combined	O
with	O
severe	O
narrowing	O
of	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
trunk	O
on	O
angiography	O
.	O
After	O
the	O
patient	O
died	O
suddenly,	O
the	O
postmortem	O
examination	O
confirmed	O
no	O
anatomic	O
or	O
pathological	O
abnormality	O
of	O
the	O
coronary	O
arteries	O
.	O
Also,	O
they	O
reported	O
that,	O
in	O
adults	O
with	O
ASD	O
and	O
pulmonary	O
hypertension,	O
the	O
coronary	O
angiography	O
revealed	O
localized	O
concave	O
narrowing	O
of	O
the	O
left	O
main	O
coronary	O
trunk	O
orifice	O
in	O
7	O
-LRB-44%-RRB-	O
of	O
16	O
patients	O
.	O
In	O
patients	O
without	O
pulmonary	O
hypertension,	O
however,	O
these	O
findings	O
were	O
not	O
observed	O
.	O
Fijiwara	O
et	O
al.7-RRB-	O
reported	O
3	O
cases	O
of	O
adult	O
ASD	O
with	O
compression	O
of	O
the	O
left	O
main	O
coronary	O
trunk	O
by	O
dilated	O
main	O
pulmonary	O
artery	O
.	O
In	O
one	O
patient	O
of	O
the	O
three,	O
magnetic	O
resonance	O
imaging	O
study	O
demonstrated	O
that	O
the	O
left	O
main	O
coronary	O
trunk	O
ran	O
close	O
to	O
the	O
left	O
main	O
pulmonary	O
artery	O
so	O
that	O
the	O
markedly	O
distended	O
pulmonary	O
artery	O
easily	O
compressed	O
the	O
left	O
main	O
coronary	O
trunk	O
.	O
In	O
two	O
of	O
the	O
three	O
cases,	O
one	O
case	O
died	O
because	O
of	O
septicemia	O
after	O
closure	O
of	O
ASD,	O
the	O
narrowed	O
left	O
main	O
coronary	O
artery	O
was	O
no	O
longer	O
narrowed	O
or	O
improved	O
the	O
severity	O
of	O
narrowing	O
after	O
closure	O
of	O
ASD	O
.	O
In	O
our	O
case,	O
pulmonary	O
hypertension	O
due	O
to	O
ASD	O
had	O
already	O
been	O
present	O
before	O
the	O
corrective	O
surgery	O
and	O
it	O
was	O
progressively	O
aggravated	O
without	O
improvement	O
after	O
the	O
correction	O
of	O
the	O
shunt	O
up	O
to	O
the	O
current	O
admission	O
.	O
Therefore,	O
the	O
left	O
main	O
coronary	O
artery	O
had	O
been	O
continuously	O
compressed,	O
in	O
spite	O
of	O
the	O
post-closure	O
status	O
for	O
ASD	O
.	O
We	O
could	O
rule	O
out	O
the	O
other	O
possible	O
reasons	O
for	O
the	O
negative	O
results	O
of	O
the	O
serologic	O
tests	O
for	O
syphilis,	O
other	O
rheumatoid	O
diseases	O
and	O
the	O
absence	O
of	O
other	O
manifestations	O
of	O
systemic	O
vasculitis	O
.	O
The	O
reason	O
for	O
disfigurement	O
of	O
the	O
left	O
side	O
ascending	O
aorta	O
and	O
the	O
ostium	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
was	O
considered	O
to	O
be	O
an	O
extrinsic	O
compression	O
owing	O
to	O
extremely	O
dilated	O
pulmonary	O
artery	O
-LRB-Figure	O
2B-RRB-	O
.	O
In	O
stenosis	O
of	O
the	O
left	O
main	O
coronary	O
artery,	O
as	O
the	O
mortality	O
rate	O
of	O
patients	O
without	O
surgical	O
treatment	O
is	O
high15-RRB-,	O
aorto-coronary	O
artery	O
bypass	O
is	O
absolutely	O
indicated6-RRB-	O
.	O
In	O
our	O
case,	O
however,	O
the	O
left	O
coronary	O
artery,	O
including	O
the	O
left	O
main	O
artery,	O
was	O
fully	O
visualized	O
with	O
collaterals	O
of	O
grade	O
III	O
from	O
the	O
right	O
coronary	O
artery	O
-LRB-Figure	O
4,	O
5-RRB-	O
which	O
explains	O
that	O
she	O
seldom	O
suffered	O
from	O
angina	O
.	O
It	O
is	O
possible	O
to	O
say	O
that	O
long-standing,	O
slowly	O
progressive	O
narrowing	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
occlusion	O
induces	O
the	O
development	O
of	O
sufficient	O
collateral	O
circulation	O
without	O
severe	O
myocardial	O
ischemia	O
.	O
Fijiwara	O
et	O
al7-RRB-	O
suggested	O
that	O
narrowing	O
of	O
the	O
left	O
main	O
coronary	O
trunk	O
improved	O
or	O
disappeared	O
after	O
ASD	O
closure,	O
thanks	O
to	O
normalization	O
of	O
pulmonary	O
flow	O
.	O
That	O
means	O
if	O
the	O
pulmonary	O
hypertension	O
is	O
reversible,	O
aorto-coronary	O
bypass	O
may	O
be	O
unnecessary	O
.	O
However,	O
in	O
our	O
experience,	O
the	O
reversibility	O
of	O
the	O
narrowing	O
of	O
the	O
left	O
coronary	O
artery	O
was	O
not	O
only	O
determined	O
by	O
the	O
ASD	O
closure	O
but	O
also	O
by	O
the	O
time	O
of	O
the	O
closure	O
.	O
The	O
narrowing	O
of	O
the	O
left	O
coronary	O
artery	O
may	O
not	O
be	O
relieved	O
after	O
operation,	O
if	O
it	O
is	O
performed	O
too	O
late	O
like	O
our	O
case	O
.	O
We	O
concluded,	O
in	O
agreement	O
with	O
previous	O
reported	O
cases47-RRB-,	O
that	O
the	O
dilated	O
pulmonary	O
artery	O
trunk	O
due	O
to	O
ASD	O
associated	O
with	O
pulmonary	O
hypertension	O
can	O
be	O
a	O
possible	O
cause	O
of	O
left	O
main	O
coronary	O
artery	O
occlusion	O
and	O
that,	O
if	O
the	O
ASD	O
closure	O
was	O
too	O
late,	O
the	O
narrowing	O
or	O
occlusion	O
of	O
the	O
left	O
coronary	O
artery	O
could	O
not	O
be	O
resolved,	O
even	O
after	O
operation,	O
owing	O
to	O
irreversible	O
pulmonary	O
hypertension	O
.	O
Prolonged	O
hyperglycemia	O
is	O
an	O
important	O
risk	O
factor	O
of	O
the	O
pathogenesis	O
of	O
diabetic	O
retinopathy	O
-LRB-DR-RRB-	O
.	O
Extracellular	O
matrix	O
molecules,	O
such	O
as	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin,	O
are	O
associated	O
with	O
fibrotic	O
membranes	O
.	O
In	O
this	O
study,	O
we	O
investigated	O
the	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
RPE	O
cells	O
under	O
high	O
glucose	O
conditions	O
.	O
Furthermore,	O
we	O
also	O
detected	O
the	O
phosphorylation	O
of	O
protein	O
kinase	O
B	O
-LRB-Akt-RRB-	O
under	O
high	O
glucose	O
conditions	O
in	O
RPE	O
cells	O
.	O
Our	O
results	O
showed	O
that	O
high	O
glucose	O
upregulated	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
expression,	O
and	O
activated	O
Akt	O
in	O
RPE	O
cells	O
.	O
We	O
also	O
found	O
that	O
pretreatment	O
with	O
LY294002	O
-LRB-an	O
inhibitor	O
of	O
phosphatidylinositol	O
3-kinase-RRB-	O
abolished	O
high	O
glucose-induced	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
RPE	O
cells	O
.	O
Thus,	O
high	O
glucose	O
induced	O
the	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
through	O
PI3K/Akt	O
signaling	O
pathway	O
in	O
RPE	O
cells,	O
and	O
the	O
PI3K/Akt	O
signaling	O
pathway	O
may	O
contribute	O
to	O
the	O
formation	O
of	O
fibrotic	O
membrane	O
during	O
the	O
development	O
of	O
DR	O
.	O
1	O
.	O
Introduction	O
Diabetic	O
retinopathy	O
-LRB-DR-RRB-	O
is	O
a	O
major	O
cause	O
of	O
adult	O
blindness	O
globally	O
-LSB-1-RSB-	O
.	O
Prolonged	O
hyperglycemia	O
plays	O
a	O
vital	O
role	O
in	O
the	O
development	O
of	O
DR	O
Increased	O
synthesis	O
of	O
extracellular	O
matrix	O
molecules	O
contributes	O
to	O
the	O
thickening	O
of	O
the	O
basement	O
membrane,	O
which	O
is	O
common	O
in	O
DR	O
-LSB-2-RSB-	O
.	O
Proliferative	O
DR,	O
an	O
advanced	O
stage	O
of	O
DR,	O
is	O
characterized	O
by	O
epiretinal	O
outgrowth	O
of	O
fibrotic	O
membranes	O
at	O
the	O
vitreoretinal	O
interface	O
.	O
Retinal	O
pigment	O
epithelial	O
-LRB-RPE-RRB-	O
cells,	O
which	O
are	O
located	O
between	O
the	O
neurosensory	O
retina	O
and	O
the	O
vascular	O
choroids,	O
form	O
the	O
outer	O
blood-retinal	O
barrier	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
pathological	O
processes	O
that	O
lead	O
to	O
the	O
loss	O
of	O
vision	O
.	O
The	O
breakdown	O
of	O
the	O
outer	O
blood-retinal	O
barrier	O
can	O
activate	O
RPE	O
cells,	O
which	O
then	O
initiate	O
proliferation	O
and	O
migration	O
and	O
secrete	O
extracellular	O
matrix	O
molecules	O
to	O
combat	O
certain	O
diseases,	O
such	O
as	O
proliferative	O
vitreoretinopathy	O
-LRB-PVR-RRB-	O
-LSB-3-RSB-,	O
proliferative	O
DR	O
-LSB-4-RSB-,	O
and	O
age-related	O
macular	O
degeneration	O
-LRB-AMD-RRB-	O
-LSB-5-RSB-	O
.	O
The	O
main	O
components	O
of	O
the	O
fibrotic	O
membranes	O
are	O
extracellular	O
matrix	O
molecules,	O
which	O
are	O
combined	O
with	O
some	O
cell	O
types	O
.	O
It	O
has	O
been	O
confirmed	O
that	O
RPE	O
and	O
other	O
cell	O
types	O
contribute	O
to	O
the	O
formation	O
of	O
fibrotic	O
membranes	O
-LSB-6,	O
7-RSB-	O
.	O
The	O
PI3K/AKT	O
pathway	O
is	O
important	O
not	O
only	O
in	O
the	O
development	O
of	O
many	O
diseases	O
but	O
also	O
for	O
signaling	O
in	O
normal	O
cells	O
.	O
This	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
numerous	O
cellular	O
functions,	O
including	O
adhesion,	O
proliferation,	O
migration,	O
invasion,	O
metabolism,	O
and	O
survival	O
-LSB-8-RSB-	O
.	O
The	O
PI3K	O
pathway	O
also	O
plays	O
an	O
essential	O
role	O
in	O
the	O
formation	O
of	O
normal	O
blood	O
vessels	O
-LSB-9-RSB-	O
.	O
The	O
PI3K/Akt	O
signaling	O
pathway	O
is	O
required	O
for	O
the	O
insulin-dependent	O
regulation	O
of	O
cellular	O
and	O
systemic	O
metabolisms	O
-LSB-10-RSB-	O
.	O
In	O
addition	O
to	O
insulin,	O
cytokines,	O
growth	B-ecosystem
factors,	I-ecosystem
and	I-ecosystem
environmental	I-ecosystem
stresses	I-ecosystem
can	I-ecosystem
activate	I-ecosystem
the	O
PI3K/Akt	O
signaling	O
pathway,	O
mainly	O
for	O
regulating	O
cell	O
proliferation,	O
motility,	O
differentiation,	O
and	O
survival	O
-LSB-11,	O
12-RSB-	O
.	O
The	O
activation	O
of	O
the	O
PI3K/Akt	O
signaling	O
pathway,	O
which	O
is	O
mediated	O
through	O
molecular	O
aberrations,	O
is	O
instrumental	O
in	O
promoting	O
the	O
development	O
of	O
tumors	O
as	O
well	O
as	O
in	O
resisting	O
anticancer	O
therapies	O
-LSB-13,	O
14-RSB-	O
.	O
It	O
has	O
been	O
reported	O
that	O
high	O
glucose	O
can	O
activate	O
the	O
PI3K/Akt	O
signaling	O
pathway	O
in	O
podocytes	O
-LSB-15-RSB-,	O
vascular	O
smooth	O
muscle	O
cells	O
-LSB-16-RSB-,	O
vascular	O
endothelial	O
cells	O
-LSB-17-RSB-,	O
and	O
human	O
pancreatic	O
cancer	O
cells	O
-LSB-18-RSB-	O
and	O
that	O
it	O
can	O
induce	O
the	O
expression	O
of	O
extracellular	O
matrix	O
molecules	O
in	O
human	O
renal	O
proximal	O
tubular	O
cells	O
-LSB-19-RSB-	O
.	O
In	O
this	O
study,	O
we	O
investigate	O
the	O
high	O
glucose-induced	O
expression	O
of	O
extracellular	O
matrix	O
molecules	O
-LRB-such	O
as	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin-RRB-,	O
the	O
phosphorylation	O
of	O
Akt,	O
and	O
the	O
mechanism	O
involved	O
in	O
the	O
high	O
glucose-induced	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
RPE	O
cells	O
.	O
2	O
.	O
Methods	O
2.1	O
.	O
Reagents	O
Anti-fibronectin	O
and	O
anti-collagen	O
IV	O
were	O
obtained	O
from	O
Abcam	O
-LRB-Danvers,	O
MA-RRB-	O
.	O
Anti-laminin	O
was	O
purchased	O
from	O
Novus	O
.	O
Anti-human	O
GAPDH	O
was	O
obtained	O
from	O
Bioworld	O
Technology,	O
Inc.	O
.	O
LY294002	O
was	O
purchased	O
from	O
Sigma	O
-LRB-St	O
Louis,	O
MO-RRB-	O
.	O
p-Akt	O
and	O
total-Akt	O
were	O
obtained	O
from	O
Cell	O
Signaling	O
Technology	O
-LRB-Danvers,	O
MA-RRB-	O
.	O
2.2	O
.	O
Cell	O
Culture	O
Human	O
RPE	O
cells	O
-LRB-ARPE-19;	O
CRL-2302-RRB-	O
were	O
purchased	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
-LRB-ATCC;	O
Manassas,	O
VA,	O
USA-RRB-	O
.	O
The	O
cells	O
were	O
cultured	O
in	O
Dulbecco's	O
Modified	O
Eagle	O
Medium	O
-LRB-DMEM;	O
Gibco,	O
Invitrogen,	O
Grand	O
Island,	O
NY-RRB-	O
with	O
10%	O
fetal	O
bovine	O
serum	O
-LRB-FBS,	O
Gibco,	O
Invitrogen-RRB-,	O
100	O
units/mL	O
penicillin,	O
and	O
100g/mL	O
streptomycin	O
-LRB-Sigma,	O
St	O
Louis,	O
MO-RRB-	O
at	O
37C	O
under	O
5%	O
CO2	O
and	O
95%	O
ambient	O
air	O
.	O
RPE	O
cells	O
were	O
seeded	O
in	O
a	O
25cm2	O
flask	O
at	O
a	O
density	O
of	O
3	O
106	O
.	O
2.3	O
.	O
Gene	O
Expression	O
Analysis	O
by	O
Real-Time	O
PCR	O
Human	O
RPE	O
cells	O
were	O
plated	O
in	O
6-well	O
culture	O
dishes	O
and	O
incubated	O
until	O
80%	O
confluence	O
was	O
reached	O
.	O
During	O
pretreatment,	O
the	O
cells	O
were	O
incubated	O
with	O
LY294002	O
for	O
12h	O
and	O
then	O
in	O
5.6mM	O
-LRB-normal	O
glucose,	O
NG-RRB-	O
or	O
25mM	O
-LRB-high	O
glucose,	O
HG-RRB-	O
glucose	O
for	O
an	O
additional	O
24h	O
.	O
The	O
total	O
RNA	O
was	O
extracted	O
from	O
RPE	O
cells	O
using	O
TRIzol	O
reagent	O
-LRB-Invitrogen,	O
Carlsbad,	O
CA-RRB-	O
according	O
to	O
the	O
manufacturer's	O
instructions	O
.	O
cDNA	O
was	O
synthesized	O
with	O
2g	O
of	O
total	O
RNA	O
using	O
a	O
RevertAid	O
First	O
Strand	O
cDNA	O
Synthesis	O
Kit	O
-LRB-Fermentas-RRB-	O
.	O
The	O
real-time	O
PCR	O
assays	O
were	O
performed	O
using	O
IQ	O
Supermix	O
-LRB-Bio-Rad,	O
Hercules,	O
CA-RRB-,	O
and	O
each	O
20L	O
reaction	O
mixture	O
contained	O
2L	O
cDNA,	O
10L	O
SYBR	O
Green	O
Real-Time	O
PCR	O
Master	O
Mix,	O
7.2L	O
sterilized	O
water,	O
and	O
0.8L	O
of	O
each	O
primer	O
-LRB-10M-RRB-	O
.	O
Amplification	O
was	O
performed	O
in	O
96-well	O
plates	O
using	O
an	O
iCycler	O
iQ	O
real-time	O
detection	O
system	O
-LRB-Bio-Rad-RRB-	O
.	O
The	O
PCR	O
primers	O
were	O
as	O
follows:	O
human	O
fibronectin:	O
forward	O
5-GAT	O
AAA	O
TCA	O
ACA	O
GTG	O
GGA	O
GC-3,	O
reverse	O
5-CCC	O
AGA	O
TCA	O
TGG	O
AGT	O
CTT	O
TA-3;	O
human	O
collagen	O
IV:	O
forward	O
5-AGA	O
GTC	O
AGC	O
ATC	O
GGC	O
TAC	O
CT-3,	O
reverse	O
5-AGG	O
AAG	O
GGC	O
ATG	O
GTG	O
CTG	O
AA-3;	O
human	O
laminin:	O
forward	O
5-CTA	O
AGC	O
TGG	O
CTC	O
CCG	O
ATG-3,	O
reverse	O
5-CAG	O
GAA	O
GAG	O
CAG	O
CAG	O
AAC	O
CT-3;	O
human	O
GAPDH:	O
forward	O
5-TGT	O
TCG	O
ACA	O
GTC	O
AGC	O
CGC	O
AT-3;	O
reverse	O
5-ACT	O
CCG	O
ACC	O
TTC	O
ACC	O
TTC	O
CC-3	O
.	O
The	O
thermocycling	O
conditions	O
were	O
3min	O
at	O
94C	O
to	O
activate	O
the	O
iTaq	O
DNA	O
polymerase,	O
39	O
cycles	O
of	O
20s	O
each,	O
94C	O
for	O
denaturation,	O
20s	O
at	O
61C	O
for	O
annealing,	O
and	O
20s	O
at	O
72C	O
for	O
extension	O
.	O
The	O
mRNA	O
expression	O
was	O
normalized	O
to	O
the	O
expression	O
level	O
of	O
GAPDH	O
and	O
was	O
calculated	O
using	O
the	O
following	O
equation:	O
Fold	O
change	O
=	O
2CT	O
.	O
2.4	O
.	O
Western	O
Blot	O
Analysis	O
Human	O
RPE	O
cells	O
were	O
grown	O
to	O
confluence	O
in	O
6-well	O
culture	O
dishes	O
and	O
were	O
incubated	O
for	O
pretreatment	O
with	O
LY294002	O
for	O
12h	O
and	O
then	O
in	O
NG	O
or	O
HG	O
glucose	O
for	O
an	O
additional	O
24h	O
.	O
Western	O
blot	O
was	O
performed	O
as	O
described	O
previously	O
-LSB-20,	O
21-RSB-	O
.	O
In	O
brief,	O
cells	O
were	O
harvested	O
and	O
lysed	O
in	O
RIPA	O
lysis	O
buffer	O
containing	O
PMSF	O
protease	O
inhibitors	O
.	O
The	O
protein	O
concentrations	O
for	O
each	O
sample	O
were	O
determined	O
using	O
the	O
bicinchoninic	O
acid	O
assay	O
-LRB-BCA-RRB-	O
.	O
Protein	O
samples	O
were	O
analyzed	O
on	O
6%	O
or	O
10%	O
SDS-PAGE	O
gels,	O
transferred	O
to	O
PVDF	O
membranes	O
-LRB-Millipore,	O
Billerica,	O
MA-RRB-,	O
and	O
processed	O
for	O
analysis	O
using	O
an	O
enhanced	O
chemiluminescence	O
-LRB-ECL-RRB-	O
detection	O
system	O
-LRB-Amersham,	O
Arlington	O
Heights,	O
IL-RRB-	O
.	O
The	O
primary	O
antibodies	O
were	O
used	O
at	O
the	O
following	O
dilutions:	O
anti-fibronectin	O
-LRB-1:1,000-RRB-,	O
anti-collagen	O
IV	O
-LRB-1:1,000-RRB-,	O
anti-laminin	O
-LRB-1:1,000-RRB-,	O
anti-p-Akt	O
-LRB-1:2000-RRB-,	O
anti-total	O
Akt	O
-LRB-1:1000-RRB-,	O
and	O
anti-GAPDH	O
-LRB-1:4,000-RRB-	O
.	O
2.5	O
.	O
Immunofluorescence	O
Staining	O
To	O
detect	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin,	O
the	O
cells	O
on	O
glass	O
coverslips	O
were	O
fixed	O
with	O
4%	O
paraformaldehyde	O
in	O
phosphate-buffered	O
saline	O
-LRB-PBS;	O
20min-RRB-,	O
washed	O
-LRB-3x,	O
PBS-RRB-,	O
and	O
0.4%	O
triton	O
X100	O
-LRB-15min-RRB-	O
.	O
Blocking	O
was	O
performed	O
with	O
10%	O
goat	O
serum	O
-LRB-1h,	O
23C-RRB-	O
.	O
Primary	O
antibodies	O
were	O
diluted	O
into	O
10%	O
goat	O
serum/PBS	O
and	O
incubated	O
overnight	O
at	O
4C	O
.	O
The	O
following	O
antibodies	O
were	O
used:	O
rabbit	O
anti-fibronectin	O
-LRB-1:100-RRB-,	O
rabbit	O
anti-collagen	O
IV	O
-LRB-1:50-RRB-,	O
and	O
rabbit	O
anti-laminin	O
-LRB-1:200-RRB-	O
.	O
Secondary	O
antibodies	O
were	O
used,	O
TRITC	O
conjugated	O
goat	O
anti-rabbit	O
IgG	O
-LRB-1:200-RRB-	O
.	O
The	O
samples	O
were	O
counterstained	O
with	O
DAPI	O
-LRB-1:1000;	O
No	O
.	O
D9542,	O
Sigma,	O
USA-RRB-	O
.	O
2.6	O
.	O
Statistical	O
Analysis	O
The	O
statistical	O
analysis	O
was	O
performed	O
using	O
SPSS	O
software	O
-LRB-version	O
17.0;	O
SPSS,	O
Inc.,	O
Chicago,	O
IL-RRB-	O
.	O
It	O
used	O
a	O
one-way	O
analysis	O
of	O
variance	O
and	O
a	O
Student's	O
t-test	O
.	O
A	O
P	O
value	O
of	O
<0.05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O
Data	O
are	O
expressed	O
as	O
means	O
standard	O
deviation	O
-LRB-SD-RRB-	O
.	O
3	O
.	O
Results	O
3.1	O
.	O
Induction	O
of	O
Fibronectin,	O
Collagen	O
IV,	O
and	O
Laminin	O
mRNA	O
and	O
Protein	O
Expression	O
under	O
High	O
Glucose	O
Conditions	O
To	O
examine	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
the	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin,	O
RPE	O
cells	O
were	O
cultured	O
in	O
Dulbecco's	O
Modified	O
Eagle	O
Medium	O
containing	O
either	O
5.5mM	O
-LRB-NG-RRB-	O
or	O
25mM	O
-LRB-HG-RRB-	O
and	O
were	O
exposed	O
for	O
24h	O
.	O
Real-time	O
PCR	O
data	O
revealed	O
increased	O
mRNA	O
levels	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
the	O
cells	O
in	O
the	O
25mM	O
medium	O
-LRB-Figures	O
1-LRB-a-RRB-1-LRB-c-RRB--RRB-	O
.	O
A	O
western	O
blot	O
analysis	O
showed	O
that	O
an	O
increased	O
protein	O
level	O
was	O
also	O
observed	O
in	O
the	O
cells	O
in	O
the	O
25mM	O
medium	O
-LRB-Figures	O
2-LRB-a-RRB-2-LRB-c-RRB--RRB-	O
.	O
3.2	O
.	O
Immunofluorescence	O
Staining	O
of	O
Fibronectin,	O
Collagen	O
IV,	O
and	O
Laminin	O
in	O
RPE	O
Cells	O
Under	O
normal	O
condition,	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
staining	O
were	O
weak	O
in	O
RPE	O
cells	O
.	O
However,	O
under	O
high	O
glucose	O
condition,	O
strong	O
positive	O
staining	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
were	O
observed	O
in	O
the	O
cytosol	O
and	O
nucleus	O
in	O
RPE	O
cells	O
-LRB-Figures	O
3-LRB-a-RRB-3-LRB-c-RRB--RRB-	O
.	O
After	O
pretreatment	O
with	O
LY294002,	O
positive	O
staining	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
were	O
inhibited	O
under	O
high	O
glucose	O
conditions	O
-LRB-Figures	O
7-LRB-a-RRB-7-LRB-c-RRB--RRB-	O
.	O
3.3	O
.	O
High	O
Glucose	O
Activates	O
PI3K/Akt	O
Signaling	O
Pathway	O
in	O
RPE	O
Cells	O
To	O
investigate	O
whether	O
high	O
glucose	O
activates	O
Akt	O
phosphorylation,	O
RPE	O
cells	O
were	O
cultured	O
in	O
Dulbecco's	O
Modified	O
Eagle	O
Medium	O
containing	O
either	O
5.5mM	O
-LRB-NG-RRB-	O
or	O
25mM	O
-LRB-HG-RRB-	O
and	O
were	O
exposed	O
for	O
5min,	O
10min,	O
or	O
30min	O
.	O
A	O
western	O
blot	O
analysis	O
showed	O
that	O
high	O
glucose	O
can	O
activate	O
the	O
phosphorylation	O
of	O
Akt	O
in	O
RPE	O
cells	O
-LRB-Figure	O
4-LRB-a-RRB--RRB-	O
.	O
The	O
phosphorylation	O
of	O
Akt	O
was	O
blocked	O
by	O
pretreatment	O
with	O
LY294002	O
under	O
high	O
glucose	O
condition	O
-LRB-Figure	O
4-LRB-b-RRB--RRB-	O
.	O
3.4	O
.	O
PI3K/Akt	O
Signaling	O
Pathway	O
Mediates	O
the	O
Expression	O
of	O
Fibronectin,	O
Collagen	O
IV,	O
and	O
Laminin	O
in	O
RPE	O
Cells	O
under	O
High	O
Glucose	O
Conditions	O
Having	O
found	O
that	O
high	O
glucose	O
activated	O
the	O
PI3K/Akt	O
signaling	O
pathways	O
and	O
induced	O
the	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
RPE	O
cells,	O
we	O
examined	O
whether	O
the	O
activation	O
of	O
the	O
PI3K/Akt	O
signaling	O
pathways	O
plays	O
a	O
vital	O
role	O
in	O
the	O
high	O
glucose-induced	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
RPE	O
cells	O
.	O
Using	O
a	O
real-time	O
PCR	O
assay,	O
pretreatment	O
of	O
RPE	O
cells	O
with	O
LY294002	O
blocked	O
the	O
high	O
glucose-induced	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
mRNA	O
-LRB-Figures	O
5-LRB-a-RRB-5-LRB-c-RRB--RRB-	O
.	O
A	O
western	O
blot	O
analysis	O
also	O
showed	O
that	O
the	O
high	O
glucose-induced	O
protein	O
levels	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
were	O
blocked	O
by	O
pretreatment	O
with	O
LY294002	O
in	O
RPE	O
cells	O
-LRB-Figures	O
6-LRB-a-RRB-6-LRB-c-RRB--RRB-	O
.	O
4	O
.	O
Discussion	O
Hyperglycemia	O
is	O
one	O
of	O
the	O
most	O
important	O
risk	O
factors	O
for	O
the	O
development	O
of	O
DR	O
Sustained	O
hyperglycemia	O
can	O
activate	O
many	O
factors,	O
cytokines,	O
and	O
other	O
molecules	O
.	O
The	O
expression	O
of	O
extracellular	O
matrix	O
molecules	O
was	O
detected	O
in	O
many	O
organs	O
of	O
diabetes	O
patients	O
and	O
cell	O
types	O
under	O
high	O
glucose	O
conditions	O
-LSB-2225-RSB-	O
.	O
It	O
has	O
also	O
been	O
proven	O
that	O
extracellular	O
matrix	O
molecules	O
are	O
involved	O
in	O
the	O
formation	O
of	O
fibrotic	O
membranes	O
and	O
the	O
thickening	O
of	O
basement	O
membrane	O
during	O
the	O
development	O
of	O
DR	O
-LSB-26-RSB-	O
.	O
In	O
the	O
present	O
study,	O
we	O
demonstrated	O
that,	O
compared	O
with	O
the	O
control	O
group,	O
high	O
glucose	O
significantly	O
increased	O
the	O
induction	O
of	O
extracellular	O
matrix	O
molecules	O
-LRB-fibronectin,	O
collagen	O
IV,	O
and	O
laminin-RRB-	O
in	O
RPE	O
cells	O
when	O
exposed	O
to	O
25mM	O
glucose	O
for	O
24h	O
.	O
However,	O
information	O
about	O
the	O
link	O
between	O
high	O
glucose	O
and	O
extracellular	O
matrix	O
molecules	O
remains	O
unclear	O
.	O
To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
by	O
which	O
high	O
glucose	O
induces	O
the	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
in	O
RPE	O
cells,	O
we	O
examined	O
intracellular	O
signaling	O
pathways	O
.	O
Our	O
results	O
showed	O
that	O
the	O
phosphorylation	O
of	O
Akt	O
was	O
activated	O
when	O
exposed	O
to	O
high	O
glucose	O
at	O
5min,	O
10min,	O
and	O
30min	O
in	O
RPE	O
cells	O
.	O
It	O
has	O
been	O
reported	O
that	O
sustained	O
endothelial	O
activation	O
of	O
Akt	O
induces	O
the	O
formation	O
of	O
structurally	O
and	O
functionally	O
abnormal	O
blood	O
vessels	O
that	O
recapitulate	O
the	O
aberrations	O
of	O
tumor	O
vessels	O
-LSB-27-RSB-	O
.	O
Studies	O
have	O
also	O
demonstrated	O
that	O
the	O
inhibition	O
of	O
Akt	O
signaling	O
could	O
inhibit	O
pathological	O
vascularization	O
-LSB-28-RSB-	O
.	O
Inhibition	O
of	O
PI3K/Akt	O
signaling	O
should	O
be	O
considered	O
especially	O
in	O
cancer	O
therapy	O
because	O
the	O
inappropriate	O
activation	O
of	O
this	O
pathway	O
is	O
frequently	O
observed	O
in	O
many	O
tumor	O
types	O
-LSB-29-RSB-	O
.	O
This	O
study	O
showed	O
that	O
the	O
expression	O
of	O
fibronectin,	O
collagen	O
IV,	O
and	O
laminin	O
was	O
significantly	O
decreased	O
when	O
pretreated	O
with	O
LY294002	O
for	O
12h	O
and	O
then	O
exposed	O
to	O
high	O
glucose	O
conditions	O
for	O
an	O
additional	O
24h	O
in	O
RPE	O
cells	O
.	O
Fibrosis	O
is	O
defined	O
as	O
the	O
excessive	O
deposition	O
of	O
extracellular	O
matrix	O
molecules	O
into	O
organs	O
and	O
tissues	O
.	O
Extracellular	O
matrix	O
molecules	O
and	O
RPE	O
cells	O
contribute	O
to	O
the	O
formation	O
of	O
fibrotic	O
membranes	O
in	O
proliferative	O
DR	O
-LSB-6,	O
7,	O
26-RSB-	O
.	O
The	O
present	O
study	O
demonstrated	O
that	O
high	O
glucose	O
significantly	O
promoted	O
the	O
induction	O
of	O
extracellular	O
matrix	O
molecules	O
and	O
the	O
phosphorylation	O
of	O
Akt	O
under	O
high	O
glucose	O
conditions	O
in	O
RPE	O
cells	O
.	O
In	O
addition,	O
inhibition	O
of	O
the	O
PI3K/Akt	O
signaling	O
pathway	O
significantly	O
decreased	O
the	O
expression	O
of	O
extracellular	O
matrix	O
molecules	O
under	O
high	O
glucose	O
conditions	O
in	O
these	O
cells	O
.	O
Thus,	O
the	O
PI3K/Akt	O
signaling	O
pathway	O
may	O
contribute	O
to	O
the	O
formation	O
of	O
fibrotic	O
membranes	O
during	O
the	O
development	O
of	O
DR	O
.	O
